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Abstract 
 A single nucleotide polymorphism in insulin-like growth factor 2 (IGF2 intron3-G3072A) 
is associated with greater muscle mass and decreased subcutaneous fat deposition in pigs 
carrying a paternal copy of the A allele (Apat). While many studies have focused on the 
differences in between the gross phenotypes of these animals, relatively little has been done to 
understand how these animals differ at the molecular level. It was the objective of this study to 
compare the molecular phenotypes of animals carrying the Apat allele and those carrying the 
Gpat allele in order to gain insight into how those differences may result in the differences seen 
at the whole-animal level. RNA was extracted from longissimus (LM) samples taken from six 
animals of each genotype (Apat and Gpat) at four different time points, fetal day 90 (d90), birth 
(0d), weaning (21d), and market weight (176d). In total 46 samples were sequenced on the 
Illumina HiSeq 2000 with a target depth of 20 million reads per sample. Analysis of the RNA-seq 
data using tweeDEseq determined differentially expressed genes between Apat and Gpat pigs at 
each time point. Additionally, IPA analysis was used to determine if there were any 
differentially activated pathways between the two phenotypes. IGF2 was not found to be 
upregulated in Apat pigs compared to Gpat at d90 or 0d; however, IGF2 expression was found to 
be increased in Apat pigs compared to Gpat pigs at 21d and 176d. Though there was not 
differential expression of IGF2 at d90 and 0d, there was still differential expression of several 
other genes at these time points. At d90, Apat pigs tended to have an increase in the expression 
anti-apoptotic genes and a decrease in pro-apoptotic genes, possibly indicating enhanced 
myoblast survival, while Gpat pigs had greater expression of genes associated with protein 
synthesis. At 0d, there was an increased expression of genes associated with proliferation and 
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protein synthesis in Apat pigs, and Gpat pigs appeared to have upregulation of genes involved in 
inflammation. At both 0d and 21d Apat and Gpat pigs had displayed upregulation of markers of 
myogenesis, suggesting different stages of muscle development. At 176d, Apat animals had 
decreased expression of genes involved in adipose signaling, including inflammation, stress, and 
autophagy and greater expression of genes associated with tissue development and the cell 
cycle. Thus, throughout the developmental timepoints, there appear to be markedly different 
processes taking place in the muscle tissue of Apat pigs and Gpat pigs. 
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Chapter1 
 Review of Literature 
Introduction 
A goal of livestock producers is to improve the production efficiency of animals while 
providing consumers with a high quality product. Over the past 60 years, the pork industry has 
selected heavily for pigs with reduced backfat thickness and increased lean percentage in 
response to changing consumer demands. Selection for leaner animals has not only reduced 
the deposition of subcutaneous fat in commercial lines but also has increased the capacity for 
muscle accretion. Consequently, the commercial swine population now exhibits a more 
muscular phenotype providing consumers with a leaner product. Due to lean accretion being 
less energetically expensive than fat accretion, the heavier muscled hogs of today are also more 
feed efficient than those of past decades. 
In order to build upon the advances made by the commercial swine industry over the 
past 60 years, it is beneficial to understand muscle growth on a molecular level and how it 
differs in these leaner, heavier muscled pigs. Muscle growth is a polygenic trait controlled by 
many genes called quantitative trait loci (QTL). Muscle growth is a complex, multistep process 
that, during embryogenesis, involves commitment of embryonic progenitor cells to a myogenic 
lineage, migration and proliferation of myoblasts, differentiation of myoblasts to myocytes, and 
the fusion of myocytes into myofibers. Postnatally, muscle growth involves the proliferation, 
differentiation, and fusion of satellite cells with the existing myofibers, thereby increasing their 
size. The added muscle growth that has resulted from the intensive selective breeding by pork 
producers suggests that one or more of these processes involved in muscle growth have been 
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altered. Thus, it is likely that many of the genes and gene networks responsible for muscle 
growth have been affected. 
 Identifying the affected genes and understanding their role in muscle growth and 
development has been the focus of much research. For the purpose of QTL mapping, 
researchers have generated large intercross swine populations and conducted genome-wide 
scans for the detection of loci influencing phenotypes. Currently, one QTL with the capability of 
explaining significant phenotypic differences in muscle mass and backfat thickness has been 
described in detail (Jeon et al., 1999; Nezer et al., 1999). This QTL is found on chromosome 2p 
near IGF2, a maternally imprinted gene known to be involved in myogenesis (Florini et al., 1991; 
Jeon et al., 1999; Nezer et al., 1999). Further investigation of the candidate QTL led to sequence 
comparison of pigs differing in QTL genotype, determined through marker-assisted segregation. 
This comparison uncovered a single nucleotide substitution (G to A) in a regulatory region of 
IGF2 (intron3-3072) that segregates perfectly between the two QTL genotypes, indicating that 
this is a quantitative trait nucleotide (QTN) underlying the QTL effect (Van Laere et al., 2003). 
Furthermore, maternal imprinting of the gene results in only the paternal allele being expressed 
in the skeletal muscle, meaning that it is the allele containing the IGF2 intron3-G3072A 
subsititution received from the sire that results in the muscular phenotype (Van Laere et al., 
2003). 
 To date, a considerable amount of research has been done to characterize the effect of 
this QTN on economically important traits of pigs. Studies indicate that the allele associated 
with greater leanness, the paternal A allele (Apat), increases the weights of heavy muscled cuts, 
such as the ham, tenderloin, shoulder, and loin, as a percentage of the carcass weight (Burgos 
3 
 
et al., 2012; Clark et al., 2014) while decreasing backfat thickness (Burgos et al., 2012; Clark et 
al., 2014; Estellé et al., 2005; Oczkowicz et al., 2009). This is done with little to no effect on 
meat quality measures (Burgos et al., 2012; Clark et al., 2014; Van den Maagdenberg et al., 
2008). Additionally, there are studies that show greater average daily gain (Oczkowicz et al., 
2009; Fontanesi et al., 2010), reduced feed intake (Oczkowicz et al., 2009), and greater carcass 
weight (Estellé et al., 2005) for certain breeds carrying the Apat allele. These data suggest that 
the Apat allele confers an economically advantageous phenotype that results in a greater 
production of lean meat and improved feed efficiency at the expense of fat deposition. 
 To elucidate the molecular basis for the observed increase in lean meat accretion, 
studies have attempted to understand how the QTN alters IGF2 expression over the course of 
swine development. Pigs carrying the Apat allele have been shown to have a three-fold increase 
of IGF2 expression in gluteus (Van Laere et al., 2003), trapezius (Gardan et al., 2008), and 
longissimus (Clark et al., 2015) muscles at three weeks of age. This increase in postnatal IGF2 
expression persists in market-aged hogs (Clark et al., 2015; Gardan et al., 2008). This 
information combined with the finding that cross-sectional area (CSA) of myofibers tended to 
be larger in Apat pigs (Gardan et al., 2008) indicate that greater lean meat accretion could be 
due, in part, to postnatal muscle hypertrophy. However, other studies indicate that the CSA of 
myofibers from Apat pigs were not different or even had a tendency to be slightly smaller than 
those from Gpat pigs (Clark et al., 2015; Van den Maagdenberg et al., 2008), suggesting that 
muscle hyperplasia is likely the cause of greater lean meat accretion. The results of Clark et al. 
(2015) supports the possibility of increased prenatal myogenesis in Apat pigs, as well; their study 
indicated that Apat fetuses tended to have greater IGF2 expression at day 90 of gestation 
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compared to Gpat fetuses, and this increase in IGF2 was associated with increased expression of 
the myogenic regulatory factors (MRFs) myogenic factor 5 (MYF5) and myogenin (MYOG). Thus, 
there is data to suggest that differential expression of IGF2 occurs late in fetal development and 
carries through to postnatal development possibly affecting both prenatal myogenesis as well 
as postnatal muscle hypertrophy. 
 The current information pertaining to IGF2 expression and the role that its QTN plays in 
muscle hyperplasia and/or hypertrophy has just begun to scratch the surface. Understanding 
how the expression of IGF2 is altered as well as the downstream pathways that are affected as 
a result of the QTN would allow us to more completely understand how the accretion of lean 
muscle may be enhanced at the molecular level. Such information could be used to make 
meaningful improvements to the performance of other production animals. Thus, a more 
comprehensive approach to studying the molecular differences between Apat and Gpat pigs is 
needed. 
Muscle Growth 
Myogenesis 
  Skeletal muscle is derived from the mesodermal germ layer of the developing embryo. 
During embryogenesis, the paraxial mesoderm condenses into paired blocks on either side of 
the midline forming somites. It is the dorsal portion of the somite, the dermamyotome, which 
develop into the skeletal muscles of the trunk and limbs (reviewed in Parker et al., 2003).  
The cells of the dermamyotome, characterized by their expression of paired-box 
transcription factors PAX3 and PAX7 (Kassar-Duchossoy et al., 2005), are encouraged to 
produce early myogenic regulatory factors (MRFs) by sonic hedgehog signaling from the 
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notochord and floor plate combined with WNT signaling from the dorsal neural tube and 
ectoderm (Munsterberg and Lassar, 1995). These early MRFs, myoblast determination protein 
(MYOD) and myogenic factor 5 (MYF5), are essential for the cells to acquire myogenic identity 
(Rudnicki et al., 1993). This activity is mediated by the beta helix-loop-helix (bHLH) domain of 
the MRFs, which facilitates transcription of muscle specific genes by binding both DNA and E 
proteins, transcription factors that recognize to the genomic E boxes in the promoters of the 
muscle specific genes (Massari and Murre, 2000). 
After commitment of the mesodermal cells to a myogenic lineage, the myoblasts must 
migrate throughout the trunk of the embryo and into the developing limb buds. This is 
accomplished by the induction of MET proto-oncogene, receptor tyrosine kinase (MET) 
expression by PAX3 (Dietrich et al., 1999). As the developing limb bud grows, scatter factor (SF) 
is secreted and binds to the MET receptor; this elicits a response that causes the cells to 
migrate towards the SF source, allowing myoblasts to move into the limb bud (Dietrich et al., 
1999). 
 Once the myoblasts have migrated throughout the body of the embryo, proliferation 
must occur to establish a pool of myoblasts that will eventually differentiate and fuse to form 
mature myofibers. Growth factors encourage proliferation by initiating pathways that prevent 
cell cycle exit during the G1 phase and promote entry into S phase (Jones and Kazlauskas, 2001). 
In addition to encouraging cellular proliferation, growth factors can also inhibit differentiation 
by promoting the activation of pathways that prevent the activity of MRFs, promoters of 
terminal differentiation, and cyclin-dependent kinase (CDK) inhibitor proteins that are 
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important for progression through the cell cycle (Rommel et al., 1999; Winter and Arnold, 
2000).  
 Cells continue to proliferate until they reach confluency. At this point, extracellular cues 
such as cadherin-mediated cell adhesion, initiate withdrawal from the cell cycle and the 
expression of genes important in myogenic differentiation, such as the secondary MRFs MYOG 
and MRF4 (Goichberg and Geiger, 1998; Hinterberger et al., 1991). IGF signaling strengthens 
this response by activating downstream targets that will halt the proliferative pathways in 
myoblasts and encourage differentiation (Lee et al., 2002). Importantly, the resulting signal 
transduction cascades stabilize MRF transcripts for translation, activate MYOD, and inhibit CDK 
activity, resulting in the expression of myogenic genes and the halt of the cell cycle  (Briata et 
al., 2005; Lluís et al., 2005; Héron-Milhavet et al., 2006; Gherzi et al., 2010). Fusion of myocytes 
immediately follows differentiation, resulting in multinucleated myotubes. Continued 
transcription of muscle-specific genes, including contractile proteins, increases the diameter of 
the myotubes and pushes nuclei to the periphery of the sarcoplasm. 
 Myogenesis generally occurs in two waves (Ashmore et al., 1972; Ashmore et al., 1973). 
Primary fiber formation occurs from day 30 to day 60 of gestation in pigs and produces 
myofibers up to six times larger than secondary fibers (Wigmore and Stickland, 1983; 
Christensen et al., 2000). Secondary fiber formation occurs from day 54 to day 90 of gestation 
and produces roughly 20 secondary myofibers for each primary myofiber (Wigmore and 
Stickland, 1983). Additionally, there is evidence of a third wave of myofiber development in 
larger animals (Mascarello et al., 1992). This wave is smaller compared to the second wave of 
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myofiber development and continues for the first three weeks of the pig’s life and (Bérard et 
al., 2011) 
Muscle Hypertrophy 
 Postnatally, skeletal muscle does not grow through the addition of new myofibers but 
through the increase in size of existing fibers; this is mediated by satellite cells located between 
the myofibers and the surrounding basal lamina (Muir et al., 1965). Satellite cells are 
undifferentiated mononucleated cells that remain quiescent until activated by signals from the 
surrounding muscle tissue, causing them to re-enter the cell cycle. These cells then proliferate 
and fuse with existing fibers, allowing for increased protein accretion. 
 Quiescent satellite cells are marked by their expression of PAX7 (Beauchamp et al., 
2000; Seale et al., 2000). Additionally, these cells express the receptor MET which binds SF 
released by muscle tissue to induce reentry into the cell cycle (Allen et al., 1995). Upon reentry 
into the cell cycle, satellite cells undergo asymmetric division, yielding daughter cells with two 
distinct fates; one daughter cell maintains satellite cell identity, replacing the original satellite 
cell, while the other daughter cell becomes a myoblast and undergoes multiple rounds of 
proliferation (Kuang et al., 2007). 
 The fate of the satellite cell-derived myoblast is very similar to that of myoblasts in 
embryonic development. Following activation, expression of MYF5 and MYOD is induced, giving 
the daughter cells a myogenic character (Cornelison and Wold, 1997). The myoblasts then 
undergo proliferation induced by FGF and IGF signaling, followed by the expression of 
secondary MRFs MYOG and MRF4 during the onset of differentiation (Allen and Boxhorn, 1989; 
Cornelison and Wold, 1997). During this time, proliferative pathways are inhibited, and IGF 
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signaling triggers pathways responsible for the expression of myogenic genes, the translation of 
protein, and the halt of the cell cycle (Allen and Boxhorn, 1989; Briata et al., 2005; Lluís et al., 
2005; Héron-Milhavet et al., 2006; Gherzi et al., 2010). Differentiated myocytes then fuse with 
the existing myofibers, enhancing their ability for protein accretion. 
Insulin-like Growth Factor 2     
 Insulin-like growth factors (IGFs) are highly conserved proteins that are necessary for 
normal growth and development in vertebrates, as they play critical roles in cellular 
proliferation, survival, and differentiation (Liu et al., 1993). The IGF family includes three 
hormones, IGF1, IGF2, and insulin; three receptors, insulin-like growth factor 1 receptor 
(IGF1R), insulin-like growth factor 2 receptor (IGF2R), and insulin receptor (IR); and six insulin-
like growth factor binding proteins (IGFBP1-6). The mature IGF2 polypeptide consists of 67 
amino acids and shares 47% identity with the mature insulin polypeptide (reviewed in O’Dell 
and Day, 1998). 
 The IGF2 gene is imprinted; thus, only one allele of the gene is expressed. In this case, it 
is the paternal allele that remains active due to maternal imprinting. This is controlled by a 
differentially methylated region (DMR) downstream of IGF2. This region on the maternal allele 
is in an unmethylated state, allowing an insulator protein, CCCTC binding factor (CTCF), to bind 
to the DMR and suppress the activity of the allele. Methylation of this DMR on the paternal 
allele abrogates CTCF binding, allowing for expression to be maintained (reviewed in Chao and 
D’Amore, 2008). 
 Generally, IGF2 expression is highest in prenatal animals, with peak levels being 3 fold 
greater than that of IGF1 (Constancia et al., 2002; reviewed in Fowden, 2003). Mice inheriting a 
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nonfunctional paternal Igf2 allele are 40% smaller than wild-type, likely owing to reduced 
proliferation (DeChiara et al., 1991). However, paternal Igf2 nulls are still viable and postnatal 
growth appears to be unaffected, underscoring Igf2’s importance as a predominantly prenatal 
growth factor (Baker et al., 1993).  
 The biological effects of IGF2 are mediated through IGF1R. Upon binding to this 
receptor, the phosphoinositide 3-kinase (PI3K)-AKT cascade and/or the mitogen-activated 
protein kinase kinase (MEK)-extracellular-regulated kinase (ERK) cascade are initiated. 
Depending on other extracellular cues and growth factor signaling that the cell is being 
subjected to, the IGF2 signal transduction cascade may result in cellular survival, proliferation, 
or differentiation. 
 The MEK-ERK pathway initiates proliferation by preventing the cell cycle exit during the 
G1 phase and promoting entry into S phase (Jones and Kazlauskas, 2001). This is accomplished 
by increasing the expression of critical cell cycle regulators, such as cyclin D1, cyclin-dependent 
kinase 4 (CDK4), and cyclin D2, and decreasing the expression of CDK inhibitors, such as p21  
(Engert et al., 1996; Rommel et al., 1999; Rosenthal and Cheng 1995). Additionally, this signal 
transduction cascade inhibits differentiation. In skeletal muscle, this is accomplished by 
preventing the nuclear accumulation of MEF2 and decreasing the expression of MYOD, 
transcription factors necessary for the expression of myogenic genes (Lassar et al., 1989; Winter 
and Arnold, 2000). 
 The PI3K-AKT cascade is involved in cellular survival. Prevention of apoptosis is achieved 
through the inhibition of several pro-apoptotic pathways and transcription factors. For 
instance, this cascade results in the phosphorylation and inactivation of the bcl-2-associated 
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death promoter (BAD) protein, which prevents them from binding and inhibiting the anti-
apoptotic proteins of the BCL-2 family (Datta et al., 1997). This pathway also inactivates 
caspases, specifically caspase 9, a protease that plays a critical role in cellular degradation 
during programmed cell death (Kermer et al., 2000). Pro-apoptotic transcription factors, such as 
the forkhead box O (FOXO) proteins, are also inhibited, reducing the expression of genes which 
initiate programmed cell death, such as FASL (Brunet et al., 1999). 
 In addition to preventing apoptosis the PI3K-AKT pathway is also critical to 
differentiation, which is marked by withdrawal from the cell cycle, the expression of tissue-
specific genes, and protein synthesis by the activation of mTOR. The cell cycle is halted through 
the increased expression of the CDK inhibitor p21 as well as the inhibition of the MEK-ERK 
pathway by inactivating the RAF protein, a protein which lies near the beginning of the signal 
transduction cascade (Lawlor and Rotwein, 2000; Rommel et al., 1999). As the cell withdrawals 
from the cell cycle, the expression of tissue-specific genes increases; in skeletal muscle these 
include secondary MRFs, MYOG and MRF4 (Musaró and Rosenthal, 1999). 
Though IGF2 is crucial to normal development and growth efficiency, an overabundance 
causes fetal overgrowth and death (Lau et al., 1994). Thus IGF2 availability is balanced by its 
binding to IGF2R and IGFBPs. In addition to limiting the availability of IGFs, IGFBPs also increase 
the half-lives of the proteins; thus, the vast majority of IGFs found in the body are not 
independently circulating, but they are bound to IGFBPs, particularly IGFBP-3 (reviewed in 
LeRoith and Roberts, 2003). The IGF2R receptor limits IGF2 availability through sequestration 
and degradation. Once IGF2 is bound to its receptor, the protein is internalized in an endosome 
and transferred to the lysosome for degradation (Jones and Clemmons, 1995). 
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IGF2 as a QTL 
 Due to its role in development and myogenesis, IGF2 was a likely candidate when a 
genome wide analysis of 677 Large White X Piétrain F2 individuals identified microsatellite 
markers located at the distal end of swine chromosome 2p associated with three of the 
phenotypes measuring muscularity and three of the phenotypes measuring fat deposition 
(Nezer et al., 1999). Similar results were found with a QTL analysis of an intercross population 
between the European Wild Boar and Large White (Jeon et al., 1999). Fluorescent in situ 
hybridization (FISH) of a BAC clone containing IGF2 with porcine metaphase chromosomes, 
confirmed its location on chromosome 2p. This QTL accounted for 15-30% of the phenotypic 
variation in muscle mass as well as 10-20% of the variation in backfat thickness (Jeon et al., 
1999; Nezer et al., 1999). 
 This QTL effect is the result of a single nucleotide substitution, IGF2-intron3-G3072A, 
which occurs in a highly conserved CpG island (Van Laere et al., 2003). Electrophoretic mobility 
shift assays (EMSAs) have shown that a repressor protein binds to the hypomethylated CpG 
island of IGF2-intron3 on the G allele; this interaction was neither present in the A allele nor the 
wild-type allele that had been methylated at the QTN site (Van Laere et al., 2003). Additionally, 
a threefold increase in IGF2 mRNA was found in postnatal skeletal muscle of pigs carrying the 
paternal A allele (Apat) compared to those carrying the paternal G allele (Gpat), which is likely the 
result abrogated repressor binding site in the Apat pigs (Van Laere et al., 2003). The function of 
this repressor, zinc finger BED-containing protein 6 (ZBED6) was later confirmed. Silencing of 
Zbed6 in mouse C2C12 myoblasts resulted in a significant increase in Igf2 expression, leading to 
12 
 
increased proliferation and faster myotube formation; whereas, overexpression of Zbed6 
decreased Igf2 expression (Markljung et al., 2009). 
Carcass and Meat Quality 
 The IGF2 A allele is economically valuable, as it has the capacity to increase average 
daily lean meat growth and lean meat percentage (Van den Maagdenberg et al., 2008). 
However, muscle yield is not the only important aspect of pork production; meat quality also 
needs to be considered. Thus, studies have been carried out with the aim of determining how 
the carcass quality of  the two IGF2 genotypes differ and whether the increase in lean meat 
associated with the IGF2 A allele is also accompanied with any decrease in meat quality 
measures. 
  These studies indicate that while ending live weight, hot carcass weight, dressing 
percentage, and chilled side weight are not significantly different between Apat and Gpat pigs, 
weights of individual cuts of meat and the percentage of the carcass that they comprise are 
significantly different between the two genotypes (Clark et al., 2014; Van den Maagdenberg et 
al., 2008). Clark et al. (2014) found that the trimmed loin, boneless Canadian back loin, back rib, 
bone-in and boneless Boston butt,  and whole and trimmed ham weights were increased in Apat 
pigs compared to Gpat pigs. Additionally, these cuts made up a larger percentage of the chilled 
side weight in Apat pigs (Clark et al., 2014). Similar results were found in previous studies with 
heavier muscled cuts, such as the loin, ham, shoulder, and tenderloin, making up a larger 
percentage of the carcass weights in Apat pigs (Burgos et al., 2012; Van den Maagdenberg et al., 
2008). These studies also found that Apat pigs had reduced backfat thickness and reduced 
weights of fattier cuts, such as the jowl and belly, comprised a smaller percentage of the 
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carcass weight in these animals (Burgos et al., 2012; Clark et al., 2014; Van den Maagdenberg et 
al., 2008). 
With regards to meat quality, there seem to be a few differences between Apat and Gpat 
pigs. Studies have shown that meat from Apat pigs tends to be lighter in color, i.e. have a larger 
L* value, than meat from Gpat pigs (Burgos et al., 2012; Clark et al., 2014; Van den Maagdenberg 
et al., 2008). These results were consistent for the longissimus dorsi, a muscle that is more 
glycolytic, and the triceps brachii, which tends to be more oxidative (Van den Maagdenberg et 
al., 2008). Additionally, the meat may have a less red color, i.e. a lower a* value (Van den 
Maagdenberg et al., 2008). However, these differences have not resulted in significantly 
different subjective color scores (Clark et al., 2014). Cooking loss may also be greater in Apat pigs 
(Clark et al., 2014), yet these results did not agree with those of previous studies (Burgos et al., 
2012; Van den Maagdenberg et al., 2008). Interestingly, studies have indicated that Apat may 
have more intramuscular fat in the longissimus dorsi (Burgos et al., 2012; Clark et al., 2014), but 
contradictory results have been found in other studies (Oczkowicz et al., 2012). 
While there are some differences in meat quality between the two genotypes, many 
measures of meat quality remain the same. No significant differences between ultimate pH, 
drip loss, subjective measures of firmness and marbling, and shear force of heated and raw 
meat have been identified between Apat and Gpat pigs (Burgos et al., 2012; Clark et al., 2014; Van 
den Maagdenberg et al., 2008). These results indicate that consumers will likely perceive meat 
from Apat pigs to be of similar quality as meat from Gpat pigs, especially since there were no 
significant differences in the subjective measures between the two genotypes. 
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Gene Expression Analysis 
 The somatic cells that make up an organism all share a common genome; it is the 
expression of different subsets and combinations of genes that allows cellular identity to 
change from tissue to tissue, enabling cells to perform specialized tasks. Changes in gene 
expression also occur during cellular development as immature cells proliferate and 
differentiate. Additionally, gene expression may be altered by growth factor signaling or 
extracellular cues, such as cell-cell contact. To understand the relationship between alterations 
in cellular phenotypes and the expression of different gene complements, researchers have 
often focused their attention on the transcriptional activity of genes. It is by comparing how the 
complement of transcriptionally active genes within cells differs between phenotypes, that 
researchers can begin to understand the functional roles of individual genes and how they 
contribute to the overall phenotype of the cell. 
 Early research methods focused primarily on the comparison of transcriptional activity 
for a single or few genes of interest between experimental conditions. For this purpose, the 
Northern blot has been the standard method for gene expression comparison for decades as it 
is capable of allowing for direct comparison of cellular RNA content without enzymatic 
manipulation. This method requires extracted RNA to be denatured and separated by gel 
electrophoresis. The separated RNA is then transferred to a nylon membrane where it is 
immobilized and washed with buffer containing labeled probes that are complementary to the 
RNA species of interest. After the probes are allowed to hybridize with the RNA, the membrane 
is washed to diminish any nonspecific binding. During visualization, the labels included in the 
probes emit a signal, and relative abundances of RNA can be compared between samples by 
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looking at the relative intensity of the signals (reviewed in Brown and Mackey, 2001; reviewed 
in Meinkoth and Wahl, 1984; Thomas, 1983). 
 Though Northern blotting is reliable and capable of discerning between relatively small 
changes in RNA expression, the amount of information that can be gained from the Northern 
blot is extremely limited (Taniguchi et al., 2001). Since there is no amplification step, this 
method is not likely to detect low to moderately abundant transcripts, as at least 100,000 
copies of a transcript are necessary for its detection by blot hybridization (Cooper, 1997). Also, 
the Northern blot is typically used to gain information about a single transcript at a time, as 
using multiple probes to detect transcripts on a single blot requires the membrane to undergo a 
time-consuming stripping process to remove the first probe before the next probe can be 
applied (Brown et al., 2004). As information can only be gained on a single transcript at a time, 
this approach does not offer researchers the ability to easily detect relationships between the 
expression of different transcripts that could possibly indicate cellular pathways or cause-effect 
relationships within the cell.  
 Thus, the ability to survey the entire complement of RNA present in the cell at one time, 
the transcriptome, would be more useful in describing cellular phenotypes. By gaining 
information on such a large number of transcripts at once, it is possible for researchers to 
detect possible cause-effect relationships of gene expression as well as identify gene networks. 
The microarray, like the Northern blot, also relies on the hybridization of RNA transcripts to a 
probe for identification, but a single microarray slide is capable of containing probes for tens of 
thousands of genes; thus, it has the ability to give researchers much more information about 
the RNA profile of the cell compared to the Northern blot (Schena et al., 1995). For this method 
16 
 
of transcript comparison, cDNA libraries must be created from the RNA of the two conditions to 
be compared. The cDNA libraries are then labeled with two different fluorescent dyes, allowing 
differential detection on two cDNA libraries at once. The libraries are then flooded onto the 
microarray slide, which contains hundreds to thousands of spots of immobilized probes with 
each spot corresponding to single transcript. As the cDNA libraries wash over the slide, the 
probes hybridize to their complementary transcripts, allowing for their detection. The 
abundance of the transcripts within each cDNA library is then determined by the color and 
intensity of the fluorescent signal (Schena et al., 1995; reviewed in Trevino et al., 2007). 
 The amount of information given by microarrays makes them an attractive choice for 
researchers looking to detect differentially expressed genes and explain phenotypic differences 
between two conditions; however, this method of transcript detection still presents several 
limitations. One such limitation is the relatively small window of relative transcript abundance 
that can be detected. Rare transcripts produce a weak signal which can be drowned out by 
background noise, nonspecific binding of transcripts to probes, and abundant transcripts are 
prone to signal saturation, a point where the signal exceeds detection threshold of the 
visualization software (Hsiao et al., 2002). Furthermore, the design of microarray and the high 
cost of producing spotted slides make pooling of biological replicates for comparison on a single 
slide attractive to researchers, who wish to limit cost and technical variation; however, this 
common practice makes it impossible to identify biological variation between replicates of the 
same condition and remove outliers (Kendziorski et al., 2005). 
 Advancements in sequencing technology, along with its increased availability have 
enabled researchers to use next-generation sequencing (NGS) as a method of transcriptome 
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interrogation. NGS technology offers ultra high-throughput sequencing by making use of 
massively parallel sequencing, where millions of sequence reads can be processed during a 
single experiment (Mardis, 2008). In response to growing amount of sequence data being 
produced, advancements in bioinformatics have also been made. With ultrahigh-throughput 
approaches available and the improved ability to analyze large amounts of sequence data, 
much more information can be gathered about cellular transcriptomes than ever before. This 
change to a global approach of transcriptome analysis frees researchers from the task of 
deciding which genes to include in an experiment and also allows for the opportunity to get 
data on new transcripts that have not yet been discovered. Data gathered through NGS can 
then be used to gain new information regarding gene networks and cause-effect relationships 
within cells. 
 The great advantages of NGS combined with dropping costs have caused high-
throughput RNA sequencing (RNA-seq) to replace microarray as the preferred method of 
transcriptome analysis (Wang et al., 2009). To prepare samples for sequencing on an NGS 
platform, total RNA extracted from cells is purified and may be depleted of ribosomal RNA at 
the discretion of the researcher. This RNA is then fragmented into 200-500 bp pieces in order to 
be compatible with deep-sequencing technologies. Following fragmentation, a cDNA library is 
created from the RNA, and adapters and indices are attached to both ends of the cDNAs to 
allow for hybridization and identification of the molecule. These libraries are then flowed onto 
the flow cell, a glass slide containing eight lanes and immobilized oligos complementary to the 
adapter sequence.  Once flooded onto the flow cell the cDNAs hybridize with immobilized 
oligos via the adapters and then are amplified by repeated replication until thousands of copies 
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of the original cDNAs have been produced.  Following amplification, the reverse strands are 
cleaved and washed away leaving the forward strand, which is identical to the original cDNA, to 
be sequenced (reviewed in Wang et al., 2009; reviewed in Zhong et al., 2011).  
The sequences of the strands are determined in a massively-parallel manner through 
sequencing by synthesis (SBS). During this process, a sequencing primer anneals to the strand 
and differentially fluorescently labeled base pairs compete for complementary binding to the 
strand. After the addition of each new nucleotide, the fluorescent label is excited by a light 
source and the characteristic emitted signal is captured by a high-speed camera. This process is 
repeated anywhere from tens to a couple hundred times depending on the needs of the 
researcher. At the end of this forward strand sequencing, the complementary sequence is 
washed away, and an index primer is annealed so that the index sequence can be determined 
for library and strand identification. If paired-end reads are desired, then following the reading 
of the first strand and its index, the molecule blocking the 3’ end of the strand is removed; thus, 
the adaptor sequence is free to fold over and bind the second oligo, creating another bridge. 
Another complementary strand is created through the elongation of this second oligo, and the 
double-stranded bridges are denatured. The forward, original strand is then cleaved from the 
oligo and washed away so that the reverse strand may be indexed and sequenced through SBS. 
The resulting sequence data can be assembled de novo or aligned to a reference sequence, and 
transcript abundance can be quantified and compared between conditions (reviewed in Hart et 
al., 2010).  
RNA-seq eliminates many problems associated with Northern blots and microarray. 
Since the only primers being used are for ligated adapter sequences, sequence data that will be 
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obtained is not limited by our current knowledge of expression profiles or genome annotation. 
Thus, in addition to known transcripts novel isoforms and previously unknown transcripts can 
be detected. RNA-seq also offers an extremely broad range for the detection of dynamic 
transcript expression, as there is no upper limit for transcript quantification and an increasing 
number of rare transcripts can be detected at greater read depths. For instance, 16 million 
reads in Saccharomyces cerevisiae resulted in a transcript expression range greater than 9,000-
fold while 40 million reads in the mouse offered a range of five orders of magnitude (Mortazavi 
et al., 2008; Nagalakshmi et al., 2008). This thorough interrogation of the transcriptome offers 
researchers more complete data for use in pathway analyses, which could lead to greater 
understanding of transcript expression profiles and cause-effect relationships within cells. 
Furthermore, RNA-seq results have been shown to be highly reproducible in both technical and 
biological replicates (Cloonan et al., 2008; Mortazavi et al., 2008). 
 Regardless of the vast benefits offered by RNA-seq, this method still has associated 
challenges. For instance, it is relatively common for sequences to map to more than one 
location in the genome. Typically, 15-20% of reads generated in humans are incapable of being 
uniquely mapped to the genome because the sequence lacks enough specificity (Wold and 
Myers, 2008). Also, since RNA-seq relies on the construction of a cDNA library prior to 
amplification, artificial differences between transcript abundance could be introduced due to 
bias inherent to PCR amplification. Nonetheless, RNA-seq still offers the most comprehensive 
method of transcriptome interrogation along with quantitative results, which makes it arguably 
the most valuable tool for understanding the molecular phenotype of cells. 
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 Differential gene expression identified by high-throughput methods like RNA-seq and 
microarray can be further validated by real-time quantitative PCR (qPCR) (Kogenaru et al. 2012). 
This method is often relied upon as a confirmatory tool because it is a fast, sensitive, 
reproducible, and quantitative approach for the comparison of gene expression (Ding et al., 
2007).  To prepare samples for qPCR, cDNA is amplified from several target RNA transcripts 
using specific primers, and as amplification occurs, fluorescent dyes are incorporated into the 
PCR product. The incorporation of these fluorescent dyes into the product allows for the 
quantification of product accumulation after every round of amplification, as the fluorescent 
signal is directly proportional to the abundance of the PCR product. The ease of use of qPCR 
and its ability to generate reproducible, quantitative information makes it ideal for use as 
confirmatory tool. Since a typical analysis only includes dozens of target transcripts of known 
identity, it does not readily lend itself to transcriptome interrogation. 
Pathway Analysis 
 High-throughput gene expression analysis has the ability to provide expression 
information on tens of thousands of gene products, and subsequent statistical analysis allows 
researchers to determine which of these gene products are differentially expressed between 
conditions or phenotypes. Typically, statistical analysis yields a list of tens or hundreds of genes 
that are differentially expressed.  However, a gene list has little explanatory power when it 
comes to describing how the underlying biology differs between phenotypes. To make 
biological sense of gene expression data, the differentially expressed genes must be considered 
within the context of the biological pathways in which they are involved.  
21 
 
 There are several methods of analyzing and explaining the biological significance of gene 
expression data, and they are constantly evolving as our knowledge base of biological pathways 
continues to grow. Over-representation analysis (ORA) has been a popular method of analyzing 
high-throughput expression data (Khatri and Drăghici 2005). This method counts the number of 
times a pathway is represented by a gene in a list differentially expressed genes. Then, a count 
of pathways represented is determined for all genes measured in the experiment. 
Hypergeometric distribution, chi-square, binomial distribution, or Fisher’s exact test is used for 
statistical analysis to determine if any pathways are over- or under-represented in the list of 
differentially expressed genes (Curtis et al., 2005; Khatri and Drăghici 2005). Unfortunately, the 
amount of information to be gained from ORA is severely limited. Regardless of the statistical 
test used, an assumption made during analysis is that the genes and pathways counted are 
independent from others in the list, which is not the case (Tian et al. 2005). This false 
assumption reduces the biological significance of the data, as the relationships between genes 
and pathways are not fully considered. Additionally, measurements associated with gene 
expression, such as fold-change in expression or p-value, are not taken into account during 
ORA, except to select differentially expressed genes (Khatri et al., 2012). Excluding this data fails 
to give weight or directionality to expression of genes or the pathways with which they are 
associated. 
 Functional class scoring (FCS) improves upon some of the shortcomings associated with 
ORA. For this method, all genes measured in the experiment are used to determine which 
pathways are represented, and the data associated with these genes, fold change and p-value, 
are used to assign a pathway-level statistic (Pavlidis et al. 2009). Thus, researchers are not 
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required to select a subset of genes for the analysis using arbitrary cutoff values, such as p-
value ≤ 0.05 or fold change ≥ 1.5, allowing for the detection of smaller, coordinated changes in 
gene expression within pathways that would have been missed by ORA (Khatri et al., 2012). 
Though FCS does consider the interdependence of gene expression within pathways, this 
analysis, like ORA, still examines each pathway independently of others (Tian et al. 2005). This 
assumption of independence ignores the fact that pathways may overlap or may ultimately 
lead to the activation of another pathway.  
 An increasingly popular method of pathway analysis is the pathway topology (PT)-based 
method. This method works similarly to FCS, as it considers all of the genes and their associated 
data before assigning a pathway-level statistic; however, unlike FCS, PT also takes into account 
the position of gene products within pathways, the interactions they have with other gene 
products, and the location of these interactions within the cell (Drăghici et al. 2007). Thus, PT 
does not simply treat pathways as gene lists as ORA and FCS do; rather, it takes advantage of 
the broader knowledge contained in databases concerning the interaction of gene products 
(Tarca et al. 2009). However, pathway annotations are far from being complete and likely 
contain incorrect information. Additionally, pathway topology is likely to be cell-specific, that is 
gene product interactions are dependent upon tissue-type and developmental stage of the cell 
(Khatri et al., 2012). 
 Unfortunately, all methods of pathway analysis are limited by our current knowledge 
about gene products and their activity within the cell; therefore, we cannot expect for any 
single method to provide a complete picture of the biological significance of differentially 
expressed genes. Moreover, these methods of pathway analysis may provide a researcher with 
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information regarding coordinated up or down regulation of gene products involved in a 
particular pathway, but depending upon the role these gene products play in the pathway, this 
may offer little to no biological insight. For instance, if the pathway is not activated due to the 
lack of signaling by a growth factor or the absence of a receptor, then the up regulation or 
down regulation of gene products downstream will likely have little or no impact on the 
physiology of the cell. These short-comings limit the amount of meaning that can be obtained 
from a list of differentially expressed genes, but that is not to imply that pathway analysis is not 
important. Applying the most current experimental data to a list of differentially expressed 
genes and considering the context of the experiment (i.e. the tissue and developmental stage) 
is critical for extracting biological relevance; however, it is equally important to recognize the 
limitations of these bioinformatics tools and to be aware of the incompleteness of the data 
they provide. 
Objectives 
 The objective of the proposed research is to more completely describe the molecular 
phenotype of pigs carrying the Apat allele of IGF2 to better understand the effect this mutation 
has on the proliferation of myoblasts and/or hypertrophy of developed muscle fibers. 
To date, much of the research regarding the IGF2 mutation has focused on the 
differential expression of IGF2, among a handful of other genes, between genotypes. Relatively 
little work has been done to define the molecular phenotype of individuals carrying the Apat 
allele of IGF2 and determine how it differs from the phenotype of the individuals carrying the 
Gpat allele outside the limited scope of real-time quantitative polymerase chain reaction (qPCR). 
RNA-seq offers the ability to characterize the molecular phenotype of the IGF2 genotypes in a 
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more detailed manner. In addition to detecting regulatory, non-coding RNAs, RNA-seq allows 
for the discovery of differential expression in genes which were not anticipated to be altered 
between genotypes. Furthermore, pathway analysis can add meaning to the differential 
expression data by indicating signal transduction cascades affected by alterations to the 
transcriptome. The global approach that RNA-seq and pathway analysis offers is advantageous 
and essential to determining the effects that the IGF2 mutation has on a trait as complex as 
muscle growth.  
         The information obtained from this research will help shed light the pathways affected 
by the economically valuable IGF2 A allele and advance our knowledge of networks involved 
muscle growth and development. Such information is critical to gaining a deeper understanding 
of the signal pathways involved in muscle growth and necessary as we look for ways to further 
improve carcass yield, meat quality, and feed efficiency of pigs and other livestock species. 
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Figure 
Figure 1. IGF2 pathway overview 
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Chapter 2 
Comparison of the Molecular Phenotype of Pigs Carrying Different IGF2 Alleles at Four 
Developmental Time Points 
Introduction 
 Insulin-like growth factor 2 (IGF2) remains one of the most well-studied quantitative 
trait loci (QTL) in commercial swine to date. Jeon et al. (1999) and Nezer et al. (1999) found this 
QTL to explain up to 20% of the variation in backfat and up to 30% of the variation in muscle 
mass within their crossbred lines. Further interrogation of the QTL identified that a single 
nucleotide polymorphism SNP, a G to A substitution in intron 3 (intron3-G3072A) of IGF2, was 
responsible for these observed phenotypic differences in fat deposition and muscle mass (Van 
Laere et al., 2003). Specifically, it is the paternal A allele (Apat) that confers the lean phenotype 
(Van Laere et al., 2003) as IGF2 is maternally imprinted; thus, only the paternal allele is 
expressed in the skeletal muscle. 
 Many studies with the aim of describing the phenotypic differences between the Apat 
and Gpat pigs have focused on carcass characteristics, economic measures, and meat quality 
measures. It is well established that Apat pigs have an economically valuable phenotype that is 
more feed efficient (Oczkowicz et al., 2009) and has a greater capacity for increased muscle 
mass (Burgos et al., 2012; Clark et al., 2014; Van den Maagdenberg et al., 2008). Additionally, 
fattier cuts of meat, such as the jowl and belly, comprise a smaller portion of the carcass weight 
in these animals as a result of reduced fat deposition (Burgos et al., 2012; Clark et al., 2014; Van 
den Maagdenberg et al., 2008). However, relatively few studies have attempted to elucidate 
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the phenotypic differences of Apat and Gpat pigs at the molecular level. Understanding how these 
genotypes differ in their muscle development and the time points at which their muscle 
development differs may offer insight to further the improvement of commercial swine 
genetics. Additionally, such information could be applied to enhance the growth of other 
livestock species. 
 The objective of the current study was to use next generation sequencing (NGS) 
technology to characterize the transcriptomes of both Apat and Gpat pigs at four developmental 
time points in order to determine how the molecular phenotype of Apat and Gpat pigs differs 
over the course of the development.  
Materials and Methods 
Animals 
 A heterozygous Berkshire boar (AG at IGF2 intron3-G3072A) was bred to homozygous 
(AA) Yorkshire-cross sows, guaranteeing that all heterozygous offspring would have inherited 
the G allele from the sire. At day 90 of gestation (d90), two sows were slaughtered to obtain 
fetuses. The 13 remaining sows were allowed to farrow. Pigs farrowed from these litters were 
harvested at birth (0d), weaning (21d), and market weight (176d). Samples from the 
longissimus (LM) muscle were collected immediately from harvested pigs, and stored at -80°C. 
Of these samples, 46 were used for RNA-seq, six samples per genotype (Apat and Gpat) from d90, 
21d, and 176d and five samples per genotype from 0d. All samples with the exception of four, 
two Apat 0d samples and two Gpat 0d samples, were placed in RNAlater (Ambion-Life 
Technologies, Grand Island, NY) to preserve the integrity of the RNA.  
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RNA-seq 
Frozen LM tissue was removed from RNAlater (Ambion-Life Technologies, Grand Island, NY), 
rinsed with water (Optima grade, Fisher Scientific, Pittsburgh, PA) and added to 1.5 ml of TRIzol 
(Ambion-Life Technologies, Grand Island, NY) for total RNA isolation according to the 
manufacturer’s instructions. Samples were homogenized using the TissueLyzer II (QIAGEN, 
Valencia, CA) and acid phenol:chloroform pH 4.5 (Ambion-Life Technologies, Grand Island, NY) 
was used to remove any remaining genomic DNA. Following RNA isolation, total RNA samples 
were purified using the RNeasy Mini Kit (QIAGEN, Valencia, CA), and the integrity of each 
sample was evaluated using the Agilent 2100 Bioanalyzer. All 46 samples had an RNA integrity 
number (RIN) greater than or equal to 8 and were considered to be of a high enough quality for 
RNA-seq. The Ribo-Zero rRNA Removal Kit (Human/Mouse/Rat) (Illumina, San Diego, CA) was 
used to deplete rRNA from 1 µg of total RNA for all samples, and TruSeq Stranded Total RNA 
sample Prep Kit (Illumina, San Diego, CA) was used to barcode the samples for identification in 
preparation for RNA sequencing. 
The 46 samples were divided into two pools, and pools were balanced with regard to 
genotype and time point. Each pool was sequenced on the Illumina HiSeq2000 for 101 cycles. 
There was a target of 20 million reads per sample with each read having a length of 100 
nucleotides. 
Differential Expression Analysis 
 Raw Illumina sequencing reads were trimmed of adapters and low-quality bases using 
Trimmomatic (v0.32) (Bolger et al., 2014). These reads were then aligned to the Sscrofa 10.2 
reference genome using TopHat2 (v2.0.13) (Kim et al., 2013), and the alignments were used by 
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Cufflinks (v2.2.1) (Trapnell et al., 2010) to create transcript assemblies for each sample. 
Cuffmerge was used to merge the transcript assemblies for each sample to create a reference 
transcriptome in the form of a GTF file for use during differential expression analysis by Cuffdiff. 
Differential expression analysis was conducted between the two genotypes, Apat and Gpat, at 
each individual time point, d90, 0d, 21d, and 176d. Furthermore, the 0d samples were analyzed 
in two different groups: all samples (n=10) and those samples that were stored in RNAlater 
(n=6). 
  Additionally, TopHat2 alignments were used by HTSeq (Anders et al., 2014) for the 
quantification of transcripts mapped to each gene or feature in the Sscrofa10.2 reference 
genome. Feature count data produced by HTSeq were used for differential expression analysis 
between genotypes at each time point in three R packages, edgeR (McCarthy et al., 2012; 
Robinson et al., 2010; Robinson and Oshlack, 2010), DESeq2 (Love et al., 2014), and tweeDEseq 
(Esnaola et al., 2013). Dam information was included as a covariate for analysis in edgeR and 
DESeq2 to improve the performance of the negative binomial model of the software. However, 
the addition of a covariate was not an option while using Cuffdiff and resulted in the loss of 
important statistical information needed for pathway analysis while using tweeDEseq; thus, 
dam information was excluded while using these tools.  
 Trimmed sequence reads were additionally aligned to reference genomes for human 
(GRCh37), mouse (NCBIM37), and cow (Btau 4.0) using STAR 2-pass (v2.4.0j) (Dobin et al., 2012) 
in order to gain information about conserved genes missing from the pig genome assembly 
(Sscrofa 10.2). STAR 2-pass was also used to realign reads to the pig genome (Sscrofa 10.2) in 
order to gain any additional information that may have not been available through the use of 
36 
 
TopHat2. These alignments were used to produce feature count data using HTSeq, and 
differential expression analysis within each species were performed using tweeDEseq. 
TweeDEseq data resulting from TopHat2 and STAR 2-pass alignments were pooled for each 
time point, and duplicates were removed from each list.  
Functional and Pathway Analyses 
Two groups of differentially expressed genes were taken from the pooled data at each 
time point, those with a false discovery rate (FDR) ≤ 0.05 and FDR ≤ 0.10. Pathway analyses for 
both groups of differentially expressed genes at each time point were carried out using the core 
analysis option of Ingenuity Pathway Analysis (IPA) software (Qiagen). Fisher’s exact test was 
used by IPA in order to determine over-represented canonical pathways. 
Results 
Reads and Alignments 
 Across the 46 samples a total of 1,266,552,669 100-nt single-end reads were generated 
with an average of 27,533,754 reads per sample. Mean quality scores per base were all above 
30 on the Solexa scale. The reads were mapped to Sscrofa10.2 using TopHat2 and STAR with an 
average of 84.54% and 72.03% uniquely mapped reads, respectively. Transcripts were also 
aligned to GRCh37, NCBIM37, and Btau 4.0 using STAR 2-pass with average of 36.25%, 20.63%, 
and 37.45% uniquely mapped reads, respectively.  
Differential Expression Analysis 
 The number of differentially expressed features (FDR ≤ 0.05) at each time point varied 
greatly between analyses carried out with Cuffdiff, edgeR, DESeq2, and tweeDEseq. Cuffdiff 
analysis, which counts differentially expressed transcripts rather than differentially expressed 
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genes (DEGs), resulted in the most differentially expressed features at each time point, and 
thus, overall. Of the software used detect DEGs from feature counts generated with HTSeq, 
tweeDEseq was able to yield the greatest number of DEGs at each time point (Table 1). 
DEGs with FDR ≤ 0.05 (Table 1) resulting from all genome alignments were pooled at 
each time point for pathway analysis. Additionally, DEGs with an FDR ≤ 0.10 were also pooled 
for submission to IPA (Table 2). The resulting number of DEGs, both with FDR ≤ 0.05 and FDR ≤ 
0.10, used as input for IPA (Qiagen) are given in Table 3. The overlap of the pooled DEGs with 
an FDR ≤ 0.10 is illustrated in Figure 2.1. There were no DEGs common to all four time points, 
yet there were several common DEGs yielded from pairwise comparisons between the 
individual time points. The only comparison that resulted in no common DEGs was d90 and 
21d. The greatest number of common DEGs across time points was 32 DEGs shared between 
176d and 0d RNAlater samples. All time points had common DEGs except for d90 and 21d. 
DEGs common to d90 samples and 0d samples tended to have a log2 fold change in opposite 
directions (Table 4).  
The top ten up- and down-regulated genes from each time point tended to be weakly 
expressed in both Apat and Gpat pigs (Table 5). The top ten highly expressed (≥ 100 counts for 
either Apat or Gpat pigs) are given in Table 6. 
Differential Expression of IGF2 
 Overall, IGF2 expression decreased over time from d90 to 176d, and differential 
expression between Apat and Gpat pigs became more pronounced after 0d (Figure 2.2). Log2 fold 
change in IGF2 expression for 21d pigs yielded from alignments to Btau 4.0, NCBIM37, and 
GRCh37 were -1.35, -1.40, and -1.45, respectively, indicating decreased expression in Gpat pigs. 
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Log2 fold change in IGF2 expression for 176d pigs yielded from alignments to Btau 4.0, 
NCBIM37, and GRCh37 were -1.66, -1.47, and -0.80, respectively. Thus, average fold change 
across all alignments for did not change considerably from 21d to 176d with respective values 
of -1.40 and -1.31. Pigs at time point d90 consistently showed slightly less IGF2 expression in 
Gpat pigs; alignments to Btau 4.0, NCBIM37, and GRCh37 resulted in a log2 fold change of -0.15,              
-0.13, and -0.05, respectively, with an average of -0.11 fold change, but difference in expression 
was not significant. None of the 0d analyses yielded a fold change indicating lower IGF2 
expression in Gpat pigs (Table 7). 
Discussion 
 Variation at IGF2 intron3-G3072A has resulted in marked phenotypic differences 
between Apat and Gpat pigs at the organismal level, and extensive research has focused on 
understanding the extent of the those phenotypic differences between Apat and Gpat pigs on a 
macro level, including measures of live pigs and carcass measures of animals after slaughter. 
Apat pigs have been shown to have reduced subcutaneous fat deposition compared to Gpat pigs, 
resulting in decreased backfat thickness (Burgos et al., 2012; Clark et al., 2014; Estellé et al., 
2005; Oczkowicz et al., 2009) and reduced yield of fattier cuts, like the jowl and belly (Burgos et 
al., 2012; Clark et al., 2014; Van den Maagdenberg et al., 2008). Additionally, the heavily 
muscled cuts of Apat pigs are generally heavier and comprise a larger proportion of the carcass 
weight when compared to heavily muscled cuts from Gpat pigs (Burgos et al., 2012; Clark et al., 
2014). Not surprisingly, it has also been shown that Apat pigs have a greater average daily gain 
of muscle compared to Gpat pigs (Van den Maagdenberg et al., 2008). 
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Although carcass differences between Apat and Gpat pigs are well established, little has 
been revealed about the phenotypic differences between Apat and Gpat pigs on a molecular 
level. Van Laere et al. (2003) concluded that there is a threefold greater expression of IGF2 in 
the skeletal muscles of three week old pigs carrying the Apat allele compared to pigs carrying the 
Gpat allele. Furthermore, increased IGF2 expression persisted in pigs aged two months, four 
months, and six months, but no significant differences in IGF2 muscle expression was 
detectable in fetal pigs (gestational day unknown, Van Laere et al., 2003). Given that IGF2 
expression is mainly increased at postnatal ages, these results suggest that postnatal muscle 
hypertrophy accounts for the organismal phenotypic differences between Apat and Gpat pigs at 
slaughter. Other evidence suggests that there is differential expression of IGF2 at as early as 
fetal day 90, lending credence to the possibility that hyperplasia may account for the 
differences in muscularity between Apat and Gpat pigs (Clark et al., 2015). The characterization of 
the molecular phenotype is incomplete; thus, the full consequence of the IGF2 intron3-G3072A 
SNP is not well understood. Moreover, it is unclear whether the IGF2 intron3-G3072A SNP 
affects muscle development and growth over the entire course of the animal’s lifetime or only 
at specific time points of the animal’s life. Therefore, the goal of the current study was to 
understand how the molecular phenotype of the skeletal muscle differs between Apat and Gpat 
pigs over the course of four developmental time points. 
Molecular Characteristics at d90 
 This study failed to detect any significant differential expression of IGF2 in the LM 
between Apat pigs and Gpat pigs at d90. This tends to support the results obtained by Van Laere 
et al. (2003), as that study also found no difference in IGF2 expression between the two 
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genotypes during prenatal development. However, the results of both of these studies 
contradict the data yielded by Clark et al. (2015), which indicated a 1.4- to 1.5-fold increase in 
IGF2 expression in the LM of Apat pigs compared to Gpat pigs. Therefore, if there is a tendency for 
prenatal hyperplasia in the skeletal muscle of Apat pigs, it is yet unclear if it is the consequence 
of increased expression of IGF2.  
Despite the failure to detect increased IGF2 expression in Apat pigs at this time point, 
there appears to be data independent of IGF2 measures that indicate the possibility of prenatal 
skeletal muscle hyperplasia in Apat pigs. Previous studies that have indicated that there is a 
tendency for Apat pigs to have a greater number of muscle fibers in the semitendinosis (ST) 
muscle when compared to the Gpat pigs, yet this increase in fiber number did not reach 
statistical significance (p≤0.05) (Clark et al., 2015; Van den Maagdenberg et al., 2008). 
Nevertheless, the ST of Apat pigs was found to be heavier despite having muscle fibers with a 
reduced cross sectional area (CSA) (Clark et al., 2015). Additionally, the LM of Apat pigs has a 
greater weight compared to Gpat pigs without any significant differences in CSA of the muscle 
fibers between the two genotypes (Clark et al., 2015; Van den Maagdenberg et al., 2008). These 
data tend to support the idea that Apat pigs have a greater number of muscle fibers with similar 
or even smaller cross sectional area compared to Gpat pigs, rather than Apat pigs having similar 
number of fibers with a greater CSA. Accordingly, the greater muscle mass found in Apat pigs 
would be the result of skeletal muscle hyperplasia in fetal pigs during one of the waves of 
muscle fiber production, as opposed to hypertrophy of the skeletal muscle during postnatal 
development. 
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The development of skeletal muscle fibers occurs in two waves (Ashmore et al., 1972; 
Ashmore et al., 1973). During the first wave primary fibers are formed, and they comprise a 
scaffold for the attachment of secondary fibers during the subsequent wave of fiber 
development (Ashmore et al., 1973). Wigmore and Stickland (1983) found that primary fibers 
were already present at day 38 of fetal development, and secondary fiber formation took place 
from day 54 to day 90 of gestation. At the end of secondary fiber formation, at day 100 of 
gestation secondary fibers account for over 90% of the total muscle fibers comprising a muscle 
(Christensen et al., 2000). Therefore, it is most likely that hyperplasia would occur during this 
second wave of muscle development and any significant differences in the molecular 
phenotype at d90 between Apat and Gpat pigs may indicate the underlying mechanism for 
hyperplasia in Apat pigs during fetal development. 
For skeletal muscle hyperplasia to occur, there must be increased myoblast proliferation 
and/or myoblast survival in order to establish a larger pool of progenitor cells for the creation 
of more myofibers. Because proliferating myoblasts are more susceptible to apoptosis 
compared to differentiated myotubes, cell survival is important for the maintenance of 
myoblast populations (Walsh, 1997). The current study found expression of IGF1R was greater 
in Apat pigs at d90 than Gpat pigs, and it is through this pathway that IGFs confer their 
proliferative and anti-apoptotic effects. Therefore, although there is not a greater expression of 
IGFs in Apat pigs, it is likely that IGFs’ effect is greater because of increased receptor expression. 
The present study also found the products of IGF signaling were upregulated in Apat pigs. 
Kruppel-like factor 6 (KLF6) is one such protein. This anti-apoptotic zinc finger protein is 
upregulated by IGF signaling (Bentov et al., 2008) and also transactivates the promoter of 
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IGF1R, increasing IGF1R expression (Rubenstein et al., 2004). Interference of KLF6 expression 
with small interfering RNAs (siRNAs) results in increased cell death and diminished 
proliferation; thus, it may play an important role in myoblast survival and proliferation 
(Rubenstein et al., 2004). It has been shown that solute carrier family 23 (ascorbic acid 
transporter), member 2 (SLC23A2) expression may be regulated by IGF signaling, as well 
(Chothe et al., 2013). The SLC23A2 gene encodes the sodium coupled vitamin C transporter 2 
(SVCT2), which allows for the uptake of ascorbic acid (vitamin C) into the cell. Evidence suggests 
that vitamin C inhibits apoptosis in myoblasts in a dose-dependent manner and may promote 
myoblast proliferation (Liu et al., 2010). Furthermore, it has been shown that cellular vitamin C 
concentrations within the muscles peak during secondary myogenesis and decay thereafter, so 
vitamin C may also be important for the early fusion of myoblasts into myotubes (Wilson, 
1990).  
Apat myoblasts and developing myotubes may also be protected by the increased 
expression of the anti-apoptotic genes glutathione S-transferase pi 1 (GSTP1) and MAX 
dimerization protein 1 (MXD1). While GSTP1 is able to prevent apoptosis in proliferating cells 
(Ishii et al., 2003), MXD1 prevents apoptosis while also inhibiting the cell cycle, which would 
protect differentiating myocytes (Gehring et al., 2000). This is compounded by the possibility of 
enhanced myoblast migration in Apat pigs indicated by increased expression of exocyst complex 
component 2 (EXOC2) and LIM domain containing preferred translocation partner in lipoma 
(LPP). EXOC2 is activated by RAS-Like protein A (RALA) downstream of IGF1R signaling 
(Moskalenko et al., 2002). RALA is essential to myoblast migration (Suzuki et al., 2000), while its 
effector, EXOC2, appears to be necessary for cells to meet their migratory potential (Wu et al., 
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2010). LPP localizes to focal adhesions (Petit et al., 2000) and also binds cytoskeleton structural 
protein α-actinin (Li et al., 2003). These focal adhesions are points of traction for the migrating 
myoblasts, as they allow the cells to make contact with the extracellular matrix.  
The developing muscles of fetal Apat pigs may be better able to support additional 
myoblasts due to the increased availability of resources for the developing cells. These animals 
were shown to have increased expression of protein kinase, AMP-activated, gamma 2 non-
catalytic subunit (PRKAG2). Expression of this gene can be induced when an energy deficit is 
detected within the cell and results in increased mitochondrial biogenesis (Zong et al., 2002) for 
greater ATP production and increased glucose uptake by muscle cells (Merrill et al., 1997). 
 Cell survival in Apat pigs is also likely enhanced by the decreased expression of the pro-
apoptotic genes G0/G1 switch 2 (G0S2) and SIVA1 apoptosis-inducing factor (SIVA1), as well as 
aryl hydrocarbon interacting protein (AIP), which has some pro-apoptotic qualities. G0S2 binds 
anti-apoptotic protein BCL-2 which prevents it from forming a heterodimer with pro-apoptotic 
protein BAX, freeing up BAX to induce cell death (Welch et al., 2009). Similarly, SIVA1 
overexpression alone has been shown to induce apoptosis (Yoon et al., 1999), as it is able to 
inhibit the effects of anti-apoptotic proteins BCL-XL and BCL-2 (Chu et al., 2004). AIP is a 
negative regulator of the alpha estrogen receptor (ERα) (Cai et al., 2011). ERα signaling has the 
ability to activate the IGF1R signal transduction cascade leading to enhanced cell survival 
(Kahlert et al., 1999); thus, the downregulation of AIP in Apat pigs may lead to additional IGF1R 
signaling through interaction with ERα. 
 Surprisingly, the downregulation of genes involved in RNA translation and processing in 
Apat pigs compared to Gpat pigs might indicate that there is faster or more efficient proliferation 
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occurring in Gpat pigs; these include genes coding for ribosomal proteins (RPS12, RPLP0P2, 
RPL37A, RP11-383610.3, RPS11P5, and RPS26) and small non-coding RNAs (SNRPD2, SNORA66, 
ACA64, SNORA64, RNU1-120P, RNU1-7P, U1, and SCARNA10). The enrichment in pathways 
involved in protein synthesis (EIF2 signaling, regualation of eIF4 and p70S6K signaling, and 
mTOR signaling) in fetal Gpat pigs compared to Apat animals, reflects the increase in ribosomal 
proteins seen in Gpat pigs. Though these enriched pathways indicate greater myoblast 
proliferation in Gpat pigs, it fails to indicate whether these myoblasts survive. In fact, the 
enriched aryl hydrocarbon signaling in the Gpat pigs may negatively affect myoblast survival. 
Furthermore, expression of proliferative markers H3 histone, family 3A (H3F3A) and histone 
cluster 1, H2ad (HIST1H2AD) offers support to the possibility that there is greater proliferation 
in Gpat animals. 
These results may be explained by the inhibition of RPTOR independent component of 
mTOR, complex 2 (RICTOR) in Gpat pigs, which was predicted by IPA upstream analysis (data not 
shown). RICTOR activation is necessary for AKT phosphorylation (Sarbassov et al., 2005), and 
AKT activity has been implicated in the upregulation of IGF1R (Tanno et al., 2001). This 
apparent differential activation of RICTOR may translate to the observed differential expression 
of IGF1R. Furthermore, mTORC2, which relies on the component RICTOR, has been shown to be 
essential for cell migration and cytoskeleton reorganization (Lang et al., 2010), both of which 
seem to be upregulated in Apat pigs compared to Gpat pigs. 
Molecular Characteristics at 0d 
 Though much of the emphasis for hyperplastic muscle growth is placed on secondary 
myotube formation, there is evidence of a third wave of myotube formation after birth 
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(Mascarello et al., 1992). Postnatal development of tertiary muscle fibers in pigs continues until 
postnatal day 28 and may account for much of the muscle growth during the first weeks of a 
pig’s life (Bérard et al., 2011). Thus, this third wave of myogenesis may also contribute to any 
hyperplastic skeletal muscle growth observed in Apat pigs. 
 As with the fetal d90 pigs, there was no evidence for differential expression of IGF2 at 
0d for either sample subsets (i.e. 0d All and 0d RNAlater). This is in contrast to the findings of 
Clark et al. (2015) whose results show a 1.5-fold increase in IGF2 expression in neonatal Apat 
pigs compared to Gpat neonates. Thus, it remains unclear if IGF2 contributes to the differing 
phenotype between Apat and Gpat pigs at this time in their development. 
 Nonetheless, Apat pigs may be experiencing postnatal hyperplastic skeletal muscle 
growth, as indicated by the upregulation of markers for RNA translation (RPS12L1, RPS29, and 
CH242-511J12.1) and non-coding RNAs responsible for RNA processing (SNORA43, SNORA60, 
SNORA71, SNORA73, SNORD112, SNORD113, SCARNA1, and U1). These genes, which play a role 
in ribosome biogenesis and RNA processing are necessary for cell growth and subsequent 
proliferation (Donati et al., 2012). Proliferation in Apat pigs may even be greater in postnatal 
muscle as eukaryotic initiation factor 2 (EIF2) signaling, which plays an important role in the 
initiation of protein synthesis, appears to be more greatly enriched in Apat pigs compared to Gpat 
pigs. This could be partially due to the decreased expression of diacylglycerol lipase alpha 
(DAGLA) in Apat pigs. This protein hydrolyzes diacylglycerol to 2-arachidonoyl glycerol, which 
activates cannabinoid receptor 1 (CB1). Signal transduction through CB1 decreases activity of 
mammalian target of rapamycin (mTOR), reducing protein synthesis (Pekkala et al., 2015). 
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The upregulation of several markers of proliferation (YRNA, HIST1H3B, SRGN, SHCBP1, 
BUB1B, and ANLN) yields support for the possibility that rapid myoblast proliferation is 
occurring in Apat pigs. YRNA expression is required for DNA replication (Christov et al., 2006), 
histone cluster 1, H3B (HIST1H3B) is upregulated during S phase of the cell cycle (Medina et al., 
2012), and  BUB1 mitotic checkpoint serine/threonine kinase B (BUB1B) expression is important 
for spindle assembly during mitosis and is important for checkpoint signaling (Bolanos-Garcia 
and Blundell, 2011). Meanwhile, the expression of actin binding protein anillin (ANLN) is 
upregulated during cellular division as it is a structural component of the cleavage furrow 
during cytokinesis (Oegema et al., 2000). SHC SH2-domain binding protein 1 (SCHBP1) appears 
to be necessary for the completion of cytokinesis, or abscission, and is degraded after mitosis 
has finished (Asano et al., 2014). Serglycin (SRGN), a proteoglycan involved in protein storage 
and secretion, has a role in myoblast proliferation that is less clear; however, it has been 
established that SRGN expression in skeletal muscle peaks in proliferating myoblast and 
decreases once differentiation has begun (Hjorth et al., 2015). 
Not only are markers of proliferation increased in Apat pigs, inhibitors of proliferation 
(let-7g and SUFU) are also downregulated in these animals with respect to Gpat pigs. MicroRNA 
let-7g represses the translation of many cell cycle related genes, which delays or even prevents 
the ability of cells to transition from G1 phase of the cell cycle to S phase (Johnson et al., 2007). 
Suppressor of fused (SUFU) inhibits sonic hedgehog (SHH) mediated proliferation by binding to 
the SHH signal mediators glioma-associated oncogenes (GLIs) and preventing the activation 
proliferation associated genes (Liu et al., 2014). 
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 In addition to actively proliferating myoblasts, Apat pigs also appear to have a large 
population of myoblasts undergoing differentiation. This is indicated by the upregulation genes 
specific to differentiating myoblasts such as myosin light chain 6 (MYL6), which is part of the 
contractile unit within the sarcomere, and myocyte enhancer factor 2c (MEF2C), a transcription 
factor exclusively expressed in myotubes. Genes associated with the progression of the 
differentiation program of myoblasts (MIR433, ASPN, and SKIL) also lend support to this. 
MicroRNA-433(MIR433) is able to allow myoblast differentiation to progress by binding to and 
repressing the activity of secreted frizzled-related protein 2 (SFRP2) (Snyder et al., 2013), a 
protein that has been shown to be an inhibitor of terminal differentiation in developing muscle 
(Descamps et al., 2008). Asporin (ASPN) and SKI-like proto-oncogene (SKIL) also inhibit the 
activity of proteins that prevent terminal differentiation of myoblasts. ASPN able to block the 
transforming growth factor-beta receptor type 2 (TGFβR2) (Nakajima et al., 2007). This stops 
the activation of its effectors, the mothers against decapentaplegic proteins (SMADs), which 
interfere with the expression of muscle-specific genes (Liu et al., 2001). SKIL, on the other hand, 
binds directly to SMAD proteins, inhibiting their ability to prevent myoblast differentiation 
(Wrighton et al., 2007). 
Myoblast differentiation and fusion into myotubes occurs nearly simultaneously, and, as 
may be expected, genes necessary for myoblast fusion (NPNT, POSTN, and F2RL2) were 
upregulated in Apat pigs alongside the aforementioned markers of myoblast differentiation. 
Nephronectin (NPNT) and periostin (POSTN) are both extra-cellular matrix proteins associated 
with the fusion of myoblasts (Sunadome et al., 2011; Özdemir et al., 2014), and coagulation 
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factor II (thrombin) receptor-like 2 (F2RL2) is an intracellular protein responsible for the 
movement of the nuclei within the myotube after fusion (Cadot et al., 2012). 
Compared to Apat pigs, Gpat pigs have a more modest increase in genes linked to 
myoblast differentiation. Gpat pigs have increased expression of nuclear factor 1 genes (NFIA 
and NFIX), which are able to associate myogenin (MYOG) and enhance the transcription of 
muscle-specific genes (Funk and Wright, 1992). Additionally, Gpat pigs have greater expression 
of PR domain containing 1 (PRDM1) which promotes slow-twitch muscle fiber identity by 
repressing genes associated with fast-twitch myofibers (von Hofsten et al., 2008). These 
animals also have increased expression of genes involved in cytoskeleton reorganization 
(WASF1 and NEK3). NIMA-related kinase 3 (NEK3) interacts with Vav 2 Guanine Nucleotide 
Exchange Factor (VAV2) to activate RAC1, a Rho family GTPase involved in myoblast fusion 
(Benjamin et al., 2011), and WAS protein family member 1 (WASF1) acts downstream of RAC1, 
resulting in nucleation of actin filaments (Eden et al., 2002). Despite the increased expression of 
these genes, Rho family GTPase signaling and actin cytoskeleton signaling appears to be more 
enriched in Apat pigs compared to Gpat pigs, possibly indicating a larger population of cells 
undergoing myoblast fusion and cytoskeleton reorganization. 
 Unlike proliferating myoblasts which rely primarily on glycolysis, these differentiating 
myotubes rely on mitochondria as their primary source of ATP, requiring oxidative 
phosphorylation to provide roughly 60% of the energy used by the cell (Leary et al., 1998). 
Therefore, mitochondrial biogenesis is greatly increased in upon differentiation of muscle cells 
(Remels et al., 2010). Thus, the enrichment of the oxidative phosphorylation pathway in Apat 
pigs may reflect a greater number of muscle fibers compared to Gpat pigs. The mitochondrial 
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dysfunction pathway was also enriched in Apat pigs; however, the gene list associated with this 
pathway was nearly identical to the list associated with oxidative phosphorylation. Thus, the 
inclusion of mitochondrial dysfunction likely reflects the increased expression of mitochondrial 
genes in Apat pigs rather than any actual pathology associated with the molecular phenotype of 
Apat pigs. 
 Interestingly, a gene associated with mitochondrial dysfunction is nearly doubled in Gpat 
pigs compared to Apat pigs. Nuclear receptor subfamily 2 group F member 2 (NR2F2) is 
upregulated in Gpat pigs and expression of this gene is inversely correlated with the expression 
of genes associated with the electron transport chain (Wu et al., 2015). Additionally, NR2F2 
inhibits myogenic differentiation by binding MYOD and its cofactor P300, preventing them from 
promoting the expression of muscle-specific genes (Bailey et al., 1998). NR2F2 also appears 
plays a crucial role in adipogenesis, as haploinsufficiency of NR2F2 has been associated with the 
reduction of white adipose tissue by up to 30% (Li et al., 2009). 
 Greater adipogenesis in Gpat pigs is also supported by the increased expression of 
ubiquitin-conjugating enzyme E2O (UBE2O), mediator complex subunit 14 (MED14), and acetyl-
CoA carboxylase beta (ACACB). UBE2O allows bone morphogenetic protein 7 (BMP7) induced 
adipocyte differentiation to progress uninhibited by inactivating SMAD6, a protein which would 
otherwise interfere with BMP7 signaling (Zhang et al., 2013). Meanwhile, MED14 interacts 
directly with peroxisome proliferator-activated receptor gamma (PPARγ), a transcription factor 
for genes involved in adipogenesis, and is necessary for the activation of adipogenic genes 
(Grøntved et al., 2010). Knockout of Acacb in mice increases fatty acid oxidation and reduces 
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accumulation of adipose tissue, indicating an important role for this gene in the storage of fat 
(Abu-Elheiga et al., 2001). 
 Greater adiposity in Gpat pigs could be linked to increased inflammation in their muscle 
tissue. Increased expression of T-cell surface glycoprotein CD4 (CD4), zeta-chain-associated 
protein 70 (ZAP70), and ring finger protein 213 (RNF213), as well as the enrichment of 
pathways involved in T-cell activation, indicate that there is likely greater inflammation 
occurring in the skeletal muscle of Gpat pigs compared to Apat pigs. CD4 is an antigen on the 
surface on T-cells, and ZAP70 is important for the activation of T-cells in the immune response 
(Reviewed in Smith-Garvin et al., 2009). While RNF213 expression has been shown to be linked 
to many cellular processes, it is also sharply upregulated in response to the release of pro-
inflammatory cytokines (Ohkubo et al., 2015). 
Molecular Characteristics at 21d 
 Unlike the previous time points, IGF2 was found to be differentially expressed in the LM 
between Apat and Gpat pigs at 21d. This is in agreement with the results found by Clark et al. 
(2015) that indicated increased IGF2 expression in the LM of Apat pigs compared to Gpat pigs at 
21d. Similarly, Van Laere et al. (2003) also described increased IGF2 expression in the muscle of 
postnatal Apat pigs compared to Gpat pigs. This increased expression IGF2 in Apat animals 
coincides with the third wave of myogenesis that has been hypothesized to exist in larger 
mammals, a process that is suggested to last until postnatal day 28 in pigs (Bérard et al., 2011). 
Therefore, it is possible that any hyperplasia observed in the muscles of Apat pigs is greatly 
impacted by the increased IGF2 expression during this time point while tertiary myofibers are 
being formed.    
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 Along with greater IGF2 expression in Apat pigs, there is also upregulation of 
synaptotagmin-like 5 (SYTL5), a gene whose product may be important in IGF2 signaling. SYTL5 
is an effector of the RAS oncogene family member RAB27A (Kuroda et al., 2002). RAB27A plays 
a role in exosome secretion and has been shown to be involved in the cellular secretion of IGF2 
(Wang et al., 2008). Thus, SYTL5 is likely a player in the autocrine signaling of IGF2 in muscle 
cells during this time point. 
 IGF2 signaling has a positive effects on myoblast proliferation (reviewed in Florini et al., 
1991) and myoblast survival (Stewart and Rotwein, 1996), and Apat pigs have increased 
expression of several markers associated with both proliferation and survival (STK26, GAB2, 
KV1.5, KCNE3, and AK4) at this time point. Serine/threonine protein kinase 26 (STK26) and 
GRB2-associated binding protein 2 (GAB2) can activate the MEK-ERK pathway (Lin et al., 2001; 
Meng et al., 2005). Enrichment of this pathway is essential to continued myoblast growth and 
proliferation, whereas, disruption of this pathway could result in premature cell cycle exit and 
differentiation (Heller et al., 2001; Jones and Kazlauskas, 2001; Volonte et al., 2005). The 
voltage-gated potassium channel genes, potassium voltage-gated channel, subfamily A, 
member 5 (KV1.5) and potassium voltage-gated channel, subfamily E, regulatory subunit 3 
(KCNE3), are also greatly expressed in proliferating myoblasts, and KV1.5 expression, in 
particular, is a driver of myoblast growth and proliferation (Villalonga et al., 2008). While 
adenylate kinase 4 (AK4) expression is associated with enhanced proliferation, it is likely that 
this is a result of its anti-apoptotic properties. AK4 is restricted to the mitochondrial matrix 
within cells (Takafumi et al., 2001) and knockdown of its expression has been associated with 
increased cell death and reduced proliferation (Kong et al., 2013; Liu et al., 2009).  
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 Despite the proliferative edge that Apat pigs appear to have, Gpat pigs do have increased 
expression of one marker of proliferation, centromere protein I (CENPI), and one possible 
marker of proliferation, ROS proto-oncogene 1, receptor tyrosine kinase (ROS1). The role of 
CENPI in proliferation is relatively clear, as it associates with kinetochores within dividing cells 
(Liu et al., 2003). However, the role of expression of ROS1 in skeletal muscle is less clear as it 
has been shown to encourage proliferation, differentiation, survival, and immune response, 
depending upon other cellular signaling (Charest et al., 2006; Schreck et al., 1992).  
 Compared to Apat pigs, Gpat pigs appear to have an upregulation of a larger number of 
genes associated with myogenic differentiation and myotube development. Cellular processes 
such as autophagy and endoplasmic reticulum (ER) stress are necessary for myoblast 
differentiation and fusion (Fortini et al., 2016; Nakanishi et al., 2005), and genes associated with 
these processes (TP53INP2, TRIM63, FBXO43, ASB11, BST1, and NFE2L3) were found to be 
increased in Gpat pigs. Tumor protein p53 inducible nuclear protein 2 (TP53INP2) is required for 
the formation of autophagosomes in cells, and thus, is a chief regulator of autophagy in skeletal 
muscle (Nowak et al., 2009). Tripartite motif containing 63 (TRIM63) and F-box protein 40 
(FBXO40) are E3 ubiquitin ligases, and the increased expression of these genes are associated 
with skeletal muscle atrophy (Bodine et al., 2001; Ye et al., 2007). While ankyrin repeat and 
SOCS box containing 11 (ASB11) is also an E3 ubiquitin ligase, it localizes to the endoplasmic 
reticulum where it is able to elicit the degradation of ribophorin 1 (RPN1), a proteasome 
subunit (Andresen et al., 2013). It is the inhibition of the proteasome that results in the 
accumulation of misfolded proteins and subsequent ER stress (Ding et al., 2007). Bone marrow 
stromal cell antigen 1 (BST1), an ER-associated protein, is necessary for the transport of 
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misfolded proteins to the Golgi apparatus (Vashist et al., 2001), and while downregulation of of 
BST1 expression promotes cytoprotective effects (Labunskyy et al., 2014), upregulation of this 
gene likely maintains ER stress. Prolonged ER stress results in the upregulation of nuclear 
factor, erythroid 2-like 3 (NFE2L3) (Pepe et al., 2010), leading to the buildup of toxic reactive 
oxygen species (ROS) within the cell (Santos et al., 2009). Taken together, these genes may 
point toward the later stages of myogenesis taking place to a greater extent in Gpat pigs 
compared to Apat pigs at this time point. 
Apat pigs do have upregulation of at least one gene that is clearly associated with 
autophagy, F-box and leucine-rich repeat protein 6 (FBXL6). The FBXL6 protein is a part of the 
SKP1-CUL1-F-box (SCF) E3 ubiquitin ligase complex, which is important for cell cycle regulation 
(Peters, 1998; Skowyra et al., 1997), rather than a modulator of skeletal muscle differentiation. 
Despite this lack of upregulation of genes associated muscle autophagy and ER stress in Apat 
pigs, there appears to be an increased expression of a few myogenic genes (CHRNE, ARG1, 
CRABP1, and COL19A1) in these animals. The acetylcholine subunit, cholinergic receptor 
nicotinic, epsilon subunit (CHRNE), is preferentially expressed in postnatal skeletal muscle 
(Mishina et al., 1986; Witzemann et al., 1987; Gu and Hall, 1988) and restricted to the end-
plates of motor neuron synapses (Schuetze and Role, 1987). Arginase 1 is highly expressed by 
M2a macrophages, a group of macrophages that are important in promoting terminal 
differentiation in myoblasts and the fusion of myoblasts into myotubes (Saclier at al., 2013). 
Likewise, retinoic acid can act as a driver of myogenic differentiation (Halevy and Lerman, 
1993), and cellular retinoic acid binding protein 1 (CRABP1), a regulator of retinoic acid 
signaling, is upregulated in cells undergoing myogenesis, with its greatest expression occurring 
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in myotubes (Zhao et al., 2014). In order to create an extracellular matrix that is capable of 
supporting the fusion of myoblasts into myotubes, differentiating myoblasts increase 
expression of collagen, type XIX, alpha 1 (COL19A1) (Sumiyoshi et al., 2001). Together, these 
genes offer evidence that the Apat pigs may still have a large number of differentiating 
myoblasts or developing myotubes this time point; however, myogenesis in Apat at this point is 
likely in a different stage of differentiation or myotube development compared to Gpat pigs. 
With increased expression of myosin heavy chain 7 (MYH7); WAP, follistatin/kazal, 
immunoglobulin, kunitz and netrin domain containing 2 (WFIKKN2); and genes associated with 
innervation of skeletal muscle (VAMP1, ALS2, and ADCY2) in Gpat pigs, it is possible that these 
animals are in later stages of myogenesis compared to Apat animals. MYH7 is the major adult 
myosin filament present in slow, oxidative type I skeletal muscles (Tajsharghi et al., 2003), and 
upregulation of MYH7 expression is an indicator of myotube maturation (Chaturvedi et al, 
2015).  Furthermore, WFIKKN2 allows for the progression of myogenesis by binding to and 
inhibiting myostatin (MSTN) (Hill et al., 2003), a negative regulator of myoblast proliferation of 
terminal myoblast differentiation (Langley et al., 2002). These genes are indicative of myotube 
development and maturation. In large mammals, myotube development is restricted to sites of 
innervation (Duxson and Sheard, 1995), and Gpat pigs have an increase of expression of genes 
associated with motor neurons. Vesicle-associated membrane protein 1 (VAMP1) is 
preferentially expressed in motor neurons in skeletal muscles (Tajika et al., 2007), while alsin 
rho guanine nucleotide exchange factor (ALS2) is important for neurite outgrowth (Tudor et al., 
2005) and motor neuron protection (Kanekura et al., 2005). As adenylate cyclase 2 (ADCY2) 
expression is found to be decreased in denervated skeletal muscle (Suzuki et al., 1998), 
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indicating that the increased expression of this gene in Gpat animals likely reflects the greater 
innervation of skeletal muscle in these pigs. 
Molecular Characteristics at 176d 
 At 176d, Apat pigs had greater expression of IGF2 in the LM compared to Gpat pigs; these 
results reflect the findings by Clark et al. (2015). At this time point, the number of myofibers 
found in the muscles is set, yet muscle cells are still able to undergo hypertrophy. Energy intake 
by the animal may also go towards hyperplasia and hypertrophy of adipose tissue. At this time 
point, evidence has shown that Apat pigs have decreased development of subcutaneous adipose 
tissue (Burgos et al., 2012; Clark et al., 2014; Estellé et al., 2005; Oczkowicz et al., 2009) and 
greater muscle mass (Burgos et al., 2012; Clark et al., 2014; Van den Maagdenberg et al., 2008) 
compared to Gpat pigs. While skeletal muscle hyperplasia early in development of  Apat pigs is a 
likely contributor to the phenotypic differences between the two genotypes, altered 
metabolism within skeletal muscle and delayed development of adipose tissue in market 
weight pigs could add to the differences between Apat and Gpat pigs, as well. 
 The Apat pigs at this time point have increased expression of genes associated with 
muscle repair (IL1RL1, LOXL3, PBX3, and S100A10) and angiogenesis (S100A10, CCDC23, and 
MYH11). Interleukin 1 receptor-like 1 (IL1RL1) is ubiquitously expressed in regulatory T cells 
found in damaged skeletal muscle, and recruitment of regulatory T cells to sites of muscle 
damage is critical for comprehensive muscle regeneration after injury (Kuswanto et al., 2016). 
Lysyl oxidase-like 3 (LOXL3) is an extracellular matrix protein that is localized at the ends of 
myofibers (Kraft-Sheleg et al., 2016), and expression of LOXL3 has been shown to be 
upregulated in response to exercise-induced hypertrophy of skeletal muscle (Palstra et al., 
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2014).  Pre-B-cell leukemia homeobox 3 (PBX3) appears to be important driver of the 
transcription of MYOD target genes during the differentiation of fast-twitch skeletal muscle 
(Berkes et al., 2004; Maves et al., 2007), and the increased expression of PBX3 is a possible 
indicator of satellite cell differentiation.  While the upregulation of S100 calcium binding 
protein A10 (S100A10) expression has been found to take place during skeletal muscle repair 
(Warren et al., 2007), it also appears to play a role in angiogenesis (Surette et al., 2011). 
Angiogenesis is able to be controlled by genes such as coiled-coil domain containing 23 
(CCDC23). The product of this gene is a chaperone protein that allows the secretion of 
angiogenic and anti-angiogenic factors, thereby regulating the process of creating new blood 
vessels (Suzuki et al., 2010; Xue et al., 2013). The walls of the blood vessels are composed of 
vascular smooth muscle whose differentiation is marked by the expression of myosin heavy 
chain 11 (MYH11), a smooth muscle specific myosin (Miano et al., 1994). 
 The continued development and repair of muscular and vascular tissues in the skeletal 
muscles of Apat pigs at this time point might be the cause of the increased expression of genes 
associated with the cell cycle (RMDN1, NUSAP1, DYRK2, PGRMC1, and 7SK). Regulator of 
microtubule dynamics 1 (RMDN1) and nucleolar and spindle associated protein 1 (NUSAP1) are 
crucial for proper chromosome segregation (Oishi et al., 2007; Raemaekers et al., 2003), and 
dual-specificity tyrosine-(Y)-phosphorylation regulated kinase 2 (DYRK2) and progesterone 
receptor membrane component 1 (PGRMC1) control the progression of the cell cycle. DYRK2 is 
able to activate p53, if necessary, to induce apoptosis (Taira et al., 2007), whereas PGRMC1 
promotes cell cycle progression and confers anti-apoptotic effects (Lin et al., 2015). While 
7SK small nuclear RNA (7SK) is not necessarily involved in the cell cycle, it may modulate the cell 
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cycle and diminish proliferation by its ability to indirectly inhibit the activity of RNA polymerase 
II and suppress the transcription of genes (Nguyen et al., 2001).   
The activity of IGF2 in Apat pigs is perhaps somewhat dampened by the increased 
expression of insulin-like binding protein 6 (IGFBP6) and the enrichment of the PTEN signaling 
pathway indicated by IPA analysis. IGFBP6 preferentially binds IGF2 (Bach et al., 1993) and 
thereby has the ability to inhibit IGF2 activity (Bach et al., 1994; Bach, 1999). Furthermore, IGF2 
enhances the expression of phosphatase and tensin homolog (PTEN), an inhibitor of IGF 
activity, acting as a negative feedback loop of IGF2 expression (Moorehead et al., 2003).  
Some of the differences seen in the molecular phenotype of Apat pigs at this time point 
may also be the result of decreased secretion of cytokines from adipose tissue (aka adipokines), 
as these animals have a significantly less amount of subcutaneous fat than Gpat animals. 
Adipose tissue releases interleukin 6 (IL-6) (Mohamed-Ali et al., 1997), adiponectin (Maeda et 
al., 1996), tumor necrosis factor-α (TNF-α) (Hotamisligil et al., 1993), and other molecules that 
alter the gene expression and pathways in nearby tissues. IPA analysis indicated that Gpat 
animals have enriched pathways that are associated with the increased expression of 
adipokines (acute phase response signaling and ciliary neurotrophic factor (CNTF) signaling) 
compared to Apat pigs, indicating that these pathways are diminished in Apat animals. IL-6 and 
TNF-α are capable of inducing acute phase response signaling, a pathway marked by systemic 
inflammation (Emery and Salmon, 1991; Castell et al., 1989). Additionally, IL-6 can upregulate 
the expression of CNTF (Shuto et al., 2001), possibly contributing the enrichment of this 
pathway in Gpat animals compared to Apat animals. These adiopokines released by subcutaneous 
adipose tissue may also increase expression of associated genes in the muscles of Gpat pigs. For 
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example, IL-6 has been shown to induce the expression of interleukin 6 signal transducer (IL6ST) 
(Fujisawa et al., 2002). Evidence suggests that adiponectin has been able to induce the 
expression of adiponectin receptor 1 (ADIPOR1) in the skeletal muscle of healthy individuals 
(McAinch et al., 2006). Also, TNF-α has been found to increase expression of pro-inflammatory 
molecule CD83 (Thurnher et al., 1997). 
Chronic inflammation, like that associated with greater adiposity and acute phase 
response signaling, leads to greater expression of p53 and p21 (Hofseth et al., 2003). The cell 
cycle genes upregulated in Gpat pigs (MKRN1 and ARID3A) appear to have roles in cell cycle 
arrest specific to the expression of p53 and p21. Under stress conditions, the pro-apoptotic 
protein p53 induces cell cycle arrest by increasing the cyclin-dependent kinase inhibitor p21, 
which represses apoptosis, but under lethal stress conditions, cell cycle arrest genes, such as 
p21, are not induced (Martinez et al., 2002; Rinaldo et al., 2007). AT rich interactive domain 3A 
(ARID3A) can be upregulated by increased p53, and together, ARID3A and p53, promote the 
transcription of p21 during stress conditions (Lestari et al., 2012). Makorin ring finger protein 1 
(MKRN1) is an E3 ubiquitin ligase that controls the degradation of p53 and p21 (Lee et al., 
2009). Under normal cellular conditions, MKRN1 promotes cell cycle progression and 
suppresses apoptosis by degrading p53; however, during cellular stress, MKRN1 promotes cell 
cycle arrest and apoptosis through the degradation of p21 (Lee et al., 2009). The greater 
expression of these genes may reflect the chronic inflammation that is associated with larger 
amounts of subcutaneous adipose tissue; therefore, the reduction of the expression of these 
genes in Apat pigs may indicate an underlying mechanism for the reduced development of 
subcutaneous adipose tissue compared to Gpat pigs. 
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Furthermore, Gpat pigs have upregulation of genes associated with cellular stress and 
autophagy (MAPKAPK3, SQSTM1, and MYBPH). Mitogen-activated protein kinase-activated 
protein kinase 3 (MAPKAPK3) is a part of the stress-activated protein kinase signaling pathway 
(Cargnello and Roux, 2011) and contributes to stress-induced autophagy (Wei et al., 2015). 
Similarly, sequestosome 1 (SQSTM1) expression is induced by cellular stress (Jain et al., 2010), 
and it associates with autophagosomes (Shvets et al., 2008). Less is known about the role of 
myosin binding protein H (MYBPH); however, some evidence has shown that it may play a role 
in autophagosome maturation (Mouton et al., 2015). 
Apart from stress- and inflammation-related genes, Gpat pigs have an increased of 
wingless-type MMTV integration site family, member 5B (WNT5B) expression. This gene may 
play roles in the regulation of skeletal muscle and the development of adipose tissue. WNT5B is 
expressed in myoblasts and myofibers of regenerating adult muscle (Polesskaya et al., 2003); 
therefore, it likely plays a role in skeletal muscle hypertrophy. However, it is also able to block 
canonical WNT signaling pathway in order to promote adipogenesis (Kanazawa et al., 2005). 
Thus, if WNT5B is able to act as a adipokine, then it may be able to induce adipogenesis in 
nearby tissue.  
There were, in fact, genes associated with adipocyte differentiation upregulated in the 
skeletal muscle of the Gpat pigs (NR6A1, FLOT1, and MRPS9). Nuclear receptor subfamily 6, 
group A, member 1 (NR6A1) is a repressor of octamer-binding transcription factor 4 (OCT4), an 
inhibitor of differentiation (Fuhrmann et al., 2001). Flotillin-1 (FLOT1) functions as a membrane-
associated protein that contributes to the trafficking of molecules via caveolae in many tissues 
(Bickel et al., 1997). Mitochondrial ribosomal protein S9 (MRPS9) is a subunit of a mitochondrial 
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ribosome. Though these proteins function in many different tissues, the expression of these 
genes have been shown to be increased during adipocyte differentiation (Bickel et al., 1997; Fu 
et al., 2005; Yin et al., 2014). The upregulation of these genes may indicate that there were 
more adipocytes in the Gpat LM samples compared to the Apat LM samples. 
Despite indicators of increased inflammation, autophagy, and possible increase of 
adipogenic genes in Gpat pigs, IPA analysis indicated that mTOR signaling, p70S6K signaling, and 
growth factor signaling were enriched in Gpat skeletal muscle. In part, this prediction could be 
due to the lower expression of IGFBP6 in Gpat pigs. However, there are genes associated with 
mTOR and p70S6K (EIF3L and EEF2) upregulated in Gpat pigs. Eukaryotic translation initiation 
factor 3, subunit L (EIF3L) is one of the 13 subunits that comprise the EIF3 complex, an integral 
component in the initiation of translational initiation (reviewed in Dong and Zhang, 2006), and 
eukaryotic translation elongation factor 2 (EEF2) is a regulator of peptide-chain elongation 
during protein synthesis during protein synthesis (reviewed in Kaul et al., 2011). The 
upregulation of these genes may suggest that Gpat pigs do have increased protein synthesis in 
their skeletal muscle tissue at this time point.  
Conclusion 
 Increased expression of IGF2 in Apat pigs was not detected until 21d; this increase in IGF2 
expression in Apat pigs persisted at 176d. Although no differential expression of IGF2 was 
detected between Apat and Gpat pigs at d90 and 0d, there was still marked differential 
expression of other genes that may contribute to their differences in phenotype. These 
differentially expressed genes at d90 and 0d may contribute to hyperplastic skeletal muscle 
growth in Apat pigs. Furthermore, increased IGF2 expression in Apat pigs may, in fact, delay the 
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progression of myogenesis in favor of greater myofiber development during tertiary 
myogenesis, as the Gpat pigs appeared to be farther along in their stages of muscle growth. At 
176d, Apat and Gpat pigs show marked differences in skeletal muscle metabolism. This is likely 
due to the combined effects of differential expression of IGF2 expression and the differences in 
quantity of adipokine signaling between the two genotypes.   
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Tables and Figures 
 
Table 1. Number of differentially expressed features between Apat and Gpat pigs with FDR ≤ 0.05 
Alignment Software Genome Used Analysis Software d90 0d All 0d RNAlater  21d 176d 
TopHat2 Sscrofa10.2 Cuffdiff 146 1142 N/A 279 560 
    edgeR (no covariate) 16 0 1 9 3 
    edgeR (covariate) 55 2 19 11 18 
    DESeq2 (covariate) 60 3 13 11 16 
    tweeDEseq  38 77 291 65 142 
STAR Sscrofa10.2 tweeDEseq  29 82 299 42 146 
STAR GRCh37 tweeDEseq  20 64 264 27 111 
STAR NCBIM37 tweeDEseq  19 45 158 11 49 
STAR Btau4.0 tweeDEseq  23 49 214 19 119 
 
Table 2. Number of DEGs yielded by tweeDEseq analysis with FDR ≤ 0.10 
Alignment Software Genome Used d90 0d  0d RNAlater 21d 176d 
TopHat2 Sscrofa10.2 55 148 394 79 255 
STAR Sscrofa10.2 45 122 409 70 255 
STAR GRCh37 52 106 420 43 187 
STAR NCBIM37 46 85 289 11 113 
STAR Btau4.0 36 114 326 34 203 
 
Table 3. Number of pooled DEGs at each time point for FDR ≤ 0.05 and FDR ≤ 0.10 used in IPA  
 Time Point Number of DEGs FDR 
d90 57 0.05 
d90 138 0.1 
0d All 137 0.05 
0d All 289 0.1 
0d RNAlater 516 0.05 
0d RNAlater 867 0.1 
21d 64 0.05 
21d 110 0.1 
176d 228 0.05 
176d 468 0.1 
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Table 4. Top ten DEGs by FDR at each time point 
Time Point Associated Gene Name Full Gene Name Counts Apat Counts Gpat Log2 Fold Change p-value FDR 
d90 KLF6 Kruppel-Like Factor 6 1944.5 1721.833 -0.1754537 3.15E-17 3.91E-13 
  LPP LIM Domain Containing Preferred 
Translocation Partner In Lipoma 
1004.5 865.333 -0.2151497 1.61E-12 2.55E-08 
  RPS12 Ribosomal Protein S12 6562.667 7872.167 0.2624786 1.32E-11 8.19E-08 
  ST8SIA2 ST8 Alpha-N-Acetyl-Neuraminide 
Alpha-2,8-Sialyltransferase 2 
59.667 126.667 1.0860398 1.90E-10 7.86E-07 
  PYGB Phosphorylase, Glycogen; Brain 152.667 73.833 -1.0480409 3.22E-10 2.07E-06 
  RPLP0P2 Ribosomal Protein, Large, P0 
Pseudogene 2 
685.667 797 0.2170723 3.10E-09 9.84E-06 
  RPL37A Ribosomal Protein L37a 1932.667 2353 0.2839085 1.31E-07 0.0003253 
  SNRPD2 Small Nuclear Ribonucleoprotein D2  437.167 514 0.233585 1.08E-07 0.000343 
  DOPEY2 Dopey Family Member 2 297.333 234 -0.3455727 2.46E-07 0.00051 
  MCM3AP Minichromosome Maintenance 
Complex Component 3 Associated 
Protein 
972.667 865.667 -0.1681339 4.83E-07 0.0007495 
0d All NFIA Nuclear Factor I/A 219.4 288 0.3925053 5.19E-11 4.14E-07 
  HECTD4 HECT Domain Containing E3 Ubiquitin 
Protein Ligase 4 
264.4 444.4 0.7491366 1.01E-08 0.000051 
  AGO1 Argonaute RISC Catalytic Component 1 80.8 117.4 0.5390052 6.13E-09 0.0000727 
  RPS12L1 Ribosomal protein S12-like 1 105 64.4 -0.7052567 9.28E-09 0.000077 
  ZAP70 Zeta-chain-associated protein 70 145 200.6 0.4682687 1.32E-08 0.000078 
  SCN4A Sodium Channel, Voltage Gated, Type 
IV Alpha Subunit 
505 974.6 0.9485268 2.40E-08 0.0000947 
  SUFU Suppressor Of Fused Homolog 31 54.8 0.8219077 3.64E-08 0.0001078 
  NR2F2 Nuclear Receptor Subfamily 2, Group 
F, Member 2 
72.4 126.6 0.8062158 5.62E-08 0.0001111 
  CH242-511J12.1 Ribosomal Protein L27A Pseuodgene 236.2 159.8 -0.5637416 1.63E-07 0.0002719 
 MED14 Mediator Complex Subunit 14 304.8 418.4 0.45701995 1.73E-07 0.0002933 
0d RNAlater F2RL2 Coagulation Factor II (Thrombin) 
Receptor-Like 2 
277.667 167.333 -0.7306291 1.32E-19 7.51E-16 
  SKIL SKI-Like Proto-Oncogene 551.667 356.333 -0.6305694 1.57E-17 5.94E-14 
  COX5B Cytochrome C Oxidase Subunit Vb 3260 2815.333 -0.2115662 1.01E-14 2.86E-11 
  MYL6 Myosin, Light Chain 6 442 306 -0.5305147 1.30E-14 5.07E-11 
  MAN2C1 Mannosidase, Alpha, Class 2C, 
Member 1 
170.333 264 0.6321771 3.85E-13 7.29E-10 
  CECR2 Cat Eye Syndrome Chromosome 
Region, Candidate 2 
58.333 123 1.0762659 1.26E-12 1.59E-09 
  KCNN3 Potassium Channel, Calcium Activated 
Intermediate/Small Conductance 
Subfamily N Alpha, Member 3 
64 179.667 1.489179 1.14E-12 1.59E-09 
  MEF2C Myocyte Enhancer Factor 2C 3313 2298.667 -0.5273409 2.00E-12 2.27E-09 
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Table 4 (cont.) 
  NR2F2 Nuclear Receptor Subfamily 2, Group 
F, Member 2 
64 122.333 0.9346738 3.48E-12 3.59E-09 
  RPS12L1 Ribosomal protein S12-like 1 102.333 52.333 -0.96747 3.32E-12 3.76E-08 
21d RAVER2 Ribonucleoprotein, PTB-Binding 2 235.667 173 -0.4459757 3.55E-11 4.17E-07 
  FRMD8 FERM Domain Containing 8 154 105.167 -0.5502528 1.95E-10 9.88E-07 
  STK26 Serine/Threonine Protein Kinase 26 124.667 80.167 -0.6370014 2.52E-10 9.88E-07 
  ASB11 Ankyrin Repeat And SOCS Box 
Containing 11, E3 Ubiquitin Protein 
Ligase 
211 325.5 0.6254145 2.52E-09 0.0000074 
  TP53INP2 Tumor Protein P53 Inducible Nuclear 
Protein 2 
198.833 285.833 0.5236145 5.08E-08 0.0001081 
  SYTL5 Synaptotagmin-Like 5 15.5 5.167 -1.5849625 2.84E-07 0.0004774 
  AGO4 Argonaute RISC Catalytic Component 4 1085.833 1515.5 0.4809912 4.31E-07 0.0006333 
  ALS2 Alsin Rho Guanine Nucleotide 
Exchange Factor 
240 290.5 0.2755038 7.33E-07 0.0009542 
  ADCY2 Adenylate Cyclase 2 1286.667 1630.667 0.3418236 1.25E-06 0.0016391 
  FAM180A Family With Sequence Similarity 180, 
Member A 
24 10 -1.2630344 2.08E-06 0.0024419 
176d GM13050 Eukaryotic Translation Elongation 
Factor Pseudogene 
1744 2184.833 0.3251232 2.97E-18 3.14E-14 
  EEF2 Eukaryotic Translation Elongation 
Factor 2 
24794 29823.833 0.2664747 4.05E-15 4.46E-11 
  EIF3L Eukaryotic Translation Initiation Factor 
3, Subunit L 
1653 1908 0.2069744 1.74E-10 6.39E-07 
  ADIPOR1 Adiponectin Receptor 1 618.5 711.5 0.2020902 4.20E-10 1.16E-06 
  FLOT1 Flotillin 1 818.667 1102 0.4287762 1.70E-09 3.12E-06 
  MAPKAPK3 Mitogen-Activated Protein Kinase-
Activated Protein Kinase 3 
374.833 484 0.3687578 2.05E-09 3.23E-06 
  IL6ST Interleukin 6 Signal Transducer 1567 1759 0.1667503 6.85E-09 9.45E-06 
  RMDN1 Regulator Of Microtubule Dynamics 1 235 184 -0.352955 8.53E-09 0.0000105 
  DYRK2 Dual-Specificity Tyrosine-(Y)-
Phosphorylation Regulated Kinase 2 
296.833 227.5 -0.3837866 3.14E-08 0.0000346 
  MKRN1 Makorin Ring Finger Protein 1 425.167 560.167 0.3978276 4.27E-08 0.0000428 
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Table 5. Top ten up- and down-regulated genes by log2 fold change for DEGs with an FDR ≤ 0.10 
Time Point 
Expression with 
Respect to Gpat Pigs Gene Symbol Full Gene Name Counts Apat Counts Gpat Log2 Fold Change p-value FDR 
d90 Down APOL5 Apolipoprotein L, 5 6.833 2.167 -1.657112286 0.000139 0.068822 
    NYX Nyctalopin 14 6.167 -1.182864057 4.11E-05 0.034284 
    PYGB Phosphorylase, Glycogen; Brain 152.667 73.833 -1.0480409 3.22E-10 2.07E-06 
    ZNF536 Zinc Finger Protein 536 18.5 10.333 -0.840219556 0.000212 0.074054 
    STK10 Serine/Threonine Kinase 10 39 24.5 -0.670692375 0.000307 0.087385 
    ZFP30 Zinc Finger Protein 30 29.667 19.333 -0.617752436 0.000299 0.089412 
    VWF Von Willebrand Factor 207.333 138.333 -0.583803244 1.20E-06 0.00255 
    MXD1 MAX Dimerization Protein 1 39.167 27.167 -0.527788792 0.000307 0.095625 
    RFX1 Regulatory Factor X, 1  62.833 44.167 -0.508572164 0.000223 0.084394 
    SPTY2D1 Suppressor Of Ty, Domain Containing 1 47.167 33.167 -0.508033622 0.000367 0.087385 
d90 Up RNU1-120P RNA, U1 Small Nuclear 120, Pseudogene 2.5 7.667 1.61667136 0.000198 0.076465 
    SNORA66 Small Nucleolar RNA, H/ACA Box 66 4.167 11.5 1.464668267 0.00023 0.082138 
    GM20721  Predicted Gene, 20721 4.5 12.333 1.454565863 0.000351 0.098152 
    ACA64 Small nucleolar RNA ACA64 13.333 34 1.350497247 7.54E-05 0.030948 
    SIVA1 SIVA1 apoptosis-Inducing Factor 5.5 13.833 1.330645312 0.000115 0.068822 
    SNORA64 Small Nucleolar RNA, H/ACA Box 64 5.167 12.833 1.31259023 0.000225 0.084394 
    RNU1-7P RNA, U1 Small Nuclear 7, Pseudogene 6 14.5 1.273018494 0.000281 0.092971 
    RP11-383G10.3  Ribosomal Protein L17 (RPL17), Pseudogene 4.833 11.167 1.208108195 0.000162 0.071563 
    U1 Small Nuclear Ribonucleoprotein Polypeptide C 12.667 28 1.144389909 0.00037 0.087385 
    ST8SIA2 ST8 Alpha-N-Acetyl-Neuraminide Alpha-2,8-
Sialyltransferase 2 
59.667 126.667 1.086039831 1.90E-10 7.86E-07 
0d All Down CFAP44 Cilia And Flagella Associated Protein 44 5.4 1 -2.432959407 0.00015 0.041845 
    HIST1H3B Histone Cluster 1, H3b 5.6 1.4 -2 0.000694 0.086049 
    SHCBP1 SHC SH2-Domain Binding Protein 1 8.4 2.6 -1.691877705 0.000106 0.034595 
    NPNT Nephronectin 15.6 5 -1.641546029 0.000773 0.082595 
    BUB1B BUB1 Mitotic Checkpoint Serine/Threonine Kinase 
B 
18.4 6 -1.61667136 0.000503 0.075542 
    MIR433 microRNA 433 20.8 7 -1.571156701 1.85E-06 0.00223 
    B3GALT2 UDP-Gal:BetaGlcNAc Beta 1,3-
Galactosyltransferase, Polypeptide 2 
11.6 4.2 -1.465663572 7.99E-05 0.021021 
    EGFL6 EGF-Like-Domain, Multiple 6 34.6 12.8 -1.434628228 8.45E-05 0.021021 
    GM26163  Predicted Gene, 6163,  snoRNA 11.8 4.6 -1.359081093 7.10E-05 0.026752 
    SNORD112 Small Nucleolar RNA, C/D Box 112 41.8 16.4 -1.349807127 0.000758 0.08168 
 66 
 
Table 5 (cont.) 
0d All Up WASF1 WAS Protein Family, Member 1 1 5 2.321928095 0.000338 0.063926 
    CD4 T-Cell Surface Glycoprotein CD4 4.8 22.2 2.209453366 0.000145 0.028579 
    DBP D Site Of Albumin Promoter (Albumin D-Box) 
Binding Protein 
3.4 9.2 1.436099115 0.000517 0.082757 
    FAM86A Eukaryotic Elongation Factor 2 Lysine 
Methyltransferase 
3.2 8.4 1.392317423 0.00083 0.090658 
    RTN4RL2 Reticulon 4 Receptor-Like 2 4.8 12.4 1.36923381 7.03E-05 0.022123 
    PARD6G Par-6 Family Cell Polarity Regulator Gamma 4.8 12.2 1.345774837 0.00061 0.081462 
    PLXNA2 Plexin A2 130.8 320 1.290709364 4.64E-07 0.000541 
    DAGLA Diacylglycerol Lipase, Alpha 22.2 53.8 1.277046496 7.21E-05 0.020159 
    CH242-280I8.1 Ferritin, Heavy Polypeptide 1 (FTH1) Pseudogene 6 14.4 1.263034406 3.20E-05 0.011163 
    PRDM1 PR Domain Containing 1, With ZNF Domain 5 11.8 1.23878686 0.000717 0.086135 
0d RNAlater Down RN7SL16P RNA, 7SL, Cytoplasmic 16, Pseudogene 7 0.667 -3.392317423 0.000685 0.042025 
    9430073C21RIK Riken cDNA 9430073C21 gene 9.333 1 -3.222392421 0.000185 0.022335 
    RN7SL782P RNA, 7SL, Cytoplasmic 782, Pseudogene 8 1 -3 9.73E-05 0.010505 
    RNU2-14P RNA, U2 Small Nuclear 14, Pseudogene 7.333 1 -2.874469118 0.000407 0.028866 
    H2-Q7 Histocompatibility 2, Q region locus 7 6.667 1 -2.736965594 0.00052 0.041786 
    MLLT11 Myeloid/Lymphoid Or Mixed-Lineage Leukemia 
(Trithorax Homolog, Drosophila); Translocated To, 
11 
13.333 2.333 -2.514573173 0.001326 0.070626 
    ANLN Anillin, Actin Binding Protein 10 2 -2.321928095 0.000825 0.054256 
    SHCBP1 SHC SH2-Domain Binding Protein 1 6.667 1.333 -2.321928095 0.001091 0.054865 
    EGFL6 EGF-Like-Domain, Multiple 6 11 2.333 -2.237039197 0.000501 0.033235 
    GM1848 Na K-ATPase beta-3 Subunit Pseudogene 10.333 2.333 -2.146841388 9.89E-05 0.014665 
0d RNAlater Up NEK3 NIMA-Related Kinase 3 0 4.333 INF 0.000312 0.031461 
    WASF1 WAS Protein Family, Member 1 0.333 5 3.906890596 0.000532 0.034673 
    RP11-277I20.3 Processed Pseudogene 0.333 4.667 3.807354922 0.001793 0.076525 
    ZFP286 Zinc Finger Protein 286 0.333 4.333 3.700439718 0.001527 0.076076 
    PROM2 Prominin 2 0.667 6.333 3.247927513 0.00026 0.020731 
    HPS1 Hermansky-Pudlak Syndrome 1 0.667 5.667 3.087462841 0.000719 0.050718 
    TMEM234 Transmembrane Protein 234 0.667 5.667 3.087462841 0.000719 0.050718 
    LET-7G MicroRNA Let-7g 1 7.333 2.874469118 0.000196 0.016743 
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    HOXA10 Homeobox A10 2.333 12.333 2.402098444 0.000996 0.059856 
    PARD6G Par-6 Family Cell Polarity Regulator Gamma  2.667 13.333 2.321928095 3.86E-06 0.00087 
21d Down SLC6A13 Solute Carrier Family 6 (Neurotransmitter 
Transporter), Member 13 
26.667 6.5 -2.036525876 0.000233 0.055921 
    CU633166.1 Tumor necrosis factor receptor superfamily 
member 11B  
22.833 7 -1.70571466 4.23E-05 0.022591 
    SYTL5 Synaptotagmin-Like 5 15.5 5.167 -1.584962501 2.84E-07 0.000477 
    GSTM5P1 Glutathione S-Transferase Mu 5 Pseudogene 1 15 5.167 -1.537656786 5.62E-06 0.008031 
    FBXL6 F-Box And Leucine-Rich Repeat Protein 6 10 3.5 -1.514573173 1.47E-05 0.015422 
    ARG1 Arginase 1 12.167 4.5 -1.434937057 0.000268 0.093757 
    CRABP1 Cellular Retinoic Acid Binding Protein 1 9.833 3.833 -1.359081093 7.02E-05 0.041388 
    IGF2 Insulin-like Growth Factor 2 693 272.167 -1.348364967 4.75E-06 0.00556 
    FAM180A Family With Sequence Similarity 180, Member A 24 10 -1.263034406 2.08E-06 0.002442 
    CHRNE Cholinergic Receptor, Nicotinic, Epsilon (Muscle) 17 8.5 -1 5.24E-05 0.01968 
21d Up AKR1C1 Aldo-Keto Reductase Family 1, Member C1 5.667 13.167 1.216317907 0.000303 0.098514 
    VAMP1 Vesicle-Associated Membrane Protein 1 
(Synaptobrevin 1) 
4.167 9.667 1.214124805 0.000292 0.097094 
    KLHL29 Kelch-Like Family Member 29 6.167 13.333 1.112474729 0.000295 0.093374 
    ROS1 ROS Proto-Oncogene 1 , Receptor Tyrosine Kinase 25.833 54.667 1.081427599 0.000252 0.093046 
    CHST9 Carbohydrate (N-Acetylgalactosamine 4-0) 
Sulfotransferase 9 
7.833 16.167 1.045323991 3.09E-05 0.025989 
    BST1 Bone Marrow Stromal Cell Antigen 1 29 56.833 0.970684433 3.60E-05 0.020162 
    WFIKKN2 WAP, Follistatin/Kazal, Immunoglobulin, Kunitz 
And Netrin Domain Containing 2 
26.667 52 0.963474124 5.22E-05 0.023626 
    GSTM3 Glutathione S-Transferase Mu 3 (Brain) 12.667 23.667 0.901819606 0.00029 0.093374 
    MYH7 Myosin, Heavy Chain 7 3823.833 7102.833 0.89337499 0.000152 0.042455 
    NFE2L3 Nuclear Factor, Erythroid 2-Like 3 37.667 63.333 0.749676646 0.000347 0.067915 
176d Down HLA-K Major Histocompatibility Complex, Class I, K 
(Pseudogene) 
6 1.5 -2 9.56E-05 0.025612 
    IGF2 Insulin-like Growth Factor 2 106 33.5 -1.661831264 3.71E-05 0.007756 
    SBSPON Somatomedin B And Thrombospondin, Type 1 
Domain Containing 
18.333 6.167 -1.571906348 3.12E-07 0.000181 
    CCDC23 Coiled-Coil Domain Containing 23 7.667 2.667 -1.523561956 0.001144 0.074091 
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    7SK RNA, 7SK Small Nuclear 12.167 4.667 -1.382469637 0.001439 0.076654 
    IL1RL1 Interleukin 1 Receptor-Like 1 12.333 4.833 -1.351472371 0.001238 0.071459 
    LOXL3 Lysyl Oxidase-Like 3 17.167 7 -1.294183104 7.64E-05 0.012039 
    MPC1 Mitochondrial Pyruvate Carrier 1 8.167 3.333 -1.292781749 0.000481 0.067829 
    TRPT1 TRNA Phosphotransferase 1 57.167 23.667 -1.272317647 0.000362 0.036948 
    NUSAP1 Nucleolar And Spindle Associated Protein 1 9.833 4.167 -1.23878686 0.000208 0.025364 
176d Up SLC26A7 Solute Carrier Family 26 (Anion Exchanger), 
Member 7 
16.167 122.333 2.919723411 3.45E-07 0.00019 
    KCNN1 Potassium Channel, Calcium Activated 
Intermediate/Small Conductance Subfamily N 
Alpha, Member 1 
1.167 5.5 2.237039197 0.00015 0.040608 
    KLHL22 Kelch-Like Family Member 22 8.667 17.667 1.027480736 1.74E-05 0.004546 
    EXD1 Exonuclease 3'-5' Domain Containing 1 9.833 19.167 0.962847002 2.20E-05 0.00571 
    MYBPH Myosin Binding Protein H 6199.833 11363.5 0.874105921 0.001997 0.090982 
    ARID3A AT Rich Interactive Domain 3A (BRIGHT-Like) 10.167 18.333 0.850622376 0.001522 0.089507 
    THEM7 Thioesterase Superfamily Member 7, Pseudogene 10.167 18.333 0.850622376 0.000229 0.049518 
    NXT2 Nuclear Transport Factor 2-Like Export Factor 2 10.667 18.667 0.807354922 0.000297 0.045305 
    NR6A1 Nuclear Receptor Subfamily 6, Group A, Member 1 16.333 27.833 0.768994448 2.25E-05 0.005388 
    WNT5B Wingless-Type MMTV Integration Site Family, 
Member 5B 
10.833 18.333 0.7589919 0.001378 0.077746 
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Table 6. Top ten up- and down- regulated highly expressed genes (≥ 100 read counts for Apat or Gpat pigs) by log2 fold change for 
DEGs with an FDR ≤ 0.10 
Time Point 
Expression with 
Respect to Gpat Pigs Gene Symbol Full Gene Name Counts Apat 
Counts 
Gpat Log2 Fold Change p-value FDR 
d90 Down PYGB Phosphorylase, Glycogen; Brain 152.667 73.833 -1.0480409 3.22E-10 2.07E-06 
    VWF Von Willebrand Factor 207.333 138.333 -0.583803244 1.20E-06 0.00255 
    GSTP1 Glutathione S-Transferase Pi 1 380.667 290.167 -0.391646448 5.34E-05 3.69E-02 
    IGF1R Insulin-Like Growth Factor 1 Receptor 427 329.667 -0.37322805 9.46E-05 0.050489 
    SLC23A2 Solute Carrier Family 23 (Ascorbic Acid 
Transporter), Member 2 
219.167 171.333 -0.355222535 0.000177 0.073432 
    PRKAG2 Protein Kinase, AMP-Activated, Gamma 2 Non-
Catalytic Subunit 
234.5 183.5 -0.35380786 0.000164 0.075536 
    DOPEY2 Dopey Family Member 2 297.333 234 -0.34557268 2.46E-07 0.00051 
    PHC1 Polyhomeotic Homolog 1 129.833 105 -0.3062715 0.000215 0.074054 
    EXTL3 Exostosin-Like Glycosyltransferase 3 187.667 152 -0.304101098 0.000112 0.068822 
    EXOC2 Exocyst Complex Component 2 116.5 95 -0.294330536 0.000293 0.089412 
d90 Up ST8SIA2 ST8 Alpha-N-Acetyl-Neuraminide Alpha-2,8-
Sialyltransferase 2 
59.667 126.667 1.086039831 1.9E-10 7.86E-07 
    GM25704 Predicted Gene, 25704 90.333 167.833 0.893698927 6.66E-05 0.04516 
    RPS11P5 Ribosomal Protein S11 Pseudogene 5 170 233.333 0.456857675 3.65E-05 0.032147 
    GM21957 Predicted Gene, 21957 134.167 182.833 0.446502837 3.48E-04 0.098152 
    G0S2 G0/G1 Switch 2 148.5 200.667 0.434338055 1.58E-06 0.002175 
    HIST1H2AD Histone Cluster 1, H2ad 269 362.833 0.431700829 0.000172 0.053038 
    SCARNA10 Small Cajal Body-Specific RNA 10 2053 2765 0.429545853 0.000188 0.074545 
    H3F3A H3 Histone, Family 3A 100.667 134.667 0.419806743 1.4E-06 0.00256 
    RPS26 Ribosomal Protein S26 1447 1919.167 0.407415083 2.34E-06 0.002397 
    AIP Aryl Hydrocarbon Receptor Interacting Protein 84.5 111.833 0.404327019 1.18E-05 1.04E-02 
0d All Down SNORD113 Small Nucleolar RNA, C/D Box 113-1 140.6 55.8 -1.333259567 6E-07 0.000646 
    SNORA43 Small Nucleolar RNA, H/ACA Box 43 174.8 80.6 -1.116853441 0.000183 0.033552 
    SRGN Serglycin 117.4 59.8 -0.973215019 4.31E-06 0.00269 
    SCARNA1 Small Cajal Body-Specific RNA 1 342 180.2 -0.924397314 0.000675 0.086049 
    SNORA71 Small Nucleolar RNA, H/ACA Box 71C 119 63.2 -0.91296511 5.7E-06 0.003366 
    SNORA60 Small Nucleolar RNA, H/ACA Box 60 101.2 55.2 -0.874469118 8.08E-06 0.005549 
    RNU1-77P RNA, U1 Small Nuclear 77, Pseudogene 261 144.6 -0.851982255 2.46E-04 0.053043 
    RN7SL444P RNA, 7SL, Cytoplasmic 444, Pseudogene 161.2 94 -0.778119082 2.44E-04 0.053043 
    RPS12L1 Ribosomal Protein S12-like 1 105 64.4 -0.705256734 9.28E-09 0.000077 
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    RPS29 Ribosomal Protein S29 138.2 87.2 -0.664357576 0.000503 0.08093 
0d All Up PLXNA2 Plexin A2 130.8 320 1.290709364 4.64E-07 0.000541 
    KCNN3 Potassium Channel, Calcium Activated 
Intermediate/Small Conductance Subfamily N 
Alpha, Member 3 
67.4 143.6 1.091235253 0.001036 0.088225 
    TLE1 Transducin-Like Enhancer Of Split 1 72.6 150.8 1.054594975 2.29E-05 0.011914 
    SCN4A Sodium Channel, Voltage Gated, Type IV Alpha 
Subunit 
505 974.6 0.948526835 2.4E-08 9.47E-05 
    RNF213 Ring Finger Protein 213 80.4 154.6 0.943272913 8.67E-05 0.021021 
    ATP2A1 ATPase, Ca++ Transporting, cardiac muscle, Fast 
Twitch 1 
11087.6 20839.2 0.910352778 0.000187 0.033552 
    PCNXL3 Pecanex-Like 3 75.4 135.4 0.84459131 1.86E-05 0.007907 
    NR2F2 Nuclear Receptor Subfamily 2, Group F, Member 2 72.4 126.6 0.806215802 5.62E-08 0.000111 
    SOGA1 Suppressor Of Glucose, Autophagy Associated 1 70.6 123.2 0.803262167 3.75E-04 0.065984 
    ACACB Acetyl-CoA Carboxylase Beta 685.6 1190.2 0.795765008 2.19E-06 0.0015 
0d RNAlater Down POSTN Periostin 2094 662.667 -1.659906186 0.000349 0.020022 
    PCDH15 Protocadherin-Related 15 103.333 34 -1.603699063 0.000214 0.013805 
    SNORA73 Small Nucleolar RNA, H/ACA Box 73 2659 1055.333 -1.333185022 1.95E-03 0.064989 
    GM23153 Predicted Gene, 23153 17854.667 7765.667 -1.201119513 1.48E-05 0.004234 
    ASPN Asporin 885.333 387.333 -1.192645078 0.000877 0.038917 
    SNORA71 Small Nucleolar RNA, H/ACA Box 71C 107.667 48.667 -1.145565796 6.7E-06 0.001104 
    COQ10B Coenzyme Q10 Homolog B 481.333 218.667 -1.138303022 0.003205 0.092694 
    U1 Small Nuclear Ribonucleoprotein Polypeptide C 3007.667 1370.667 -1.133766921 2.6E-09 1.85E-06 
    RN7SL444P RNA, 7SL, Cytoplasmic 444, Pseudogene 142.333 65 -1.130761946 1.78E-07 0.000113 
    Y RNA Y RNA 221.333 103.667 -1.094268661 1.02E-03 0.041931 
0d RNAlater Up KCNN3 Potassium Channel, Calcium Activated 
Intermediate/Small Conductance Subfamily N 
Alpha, Member 3 
64 179.667 1.489178962 1.14E-12 1.59E-09 
    PLXNA2 Plexin A2 126.333 313 1.308927309 1.54E-05 0.001865 
    POLR2A Polymerase (RNA) II (DNA Directed) Polypeptide A 115 248.667 1.112579269 0.00061 0.0295 
    CECR2 Cat Eye Syndrome Chromosome Region, Candidate 
2 
58.333 123 1.076265894 1.26E-12 1.59E-09 
    SCN4A Sodium Channel, Voltage Gated, Type IV Alpha 
Subunit 
508 1027.667 1.016471987 2.95E-08 1.34E-05 
    TLE1 Transducin-Like Enhancer Of Split 1 78.333 157.333 1.006126103 0.000026 0.003631 
    SUMF2 Sulfatase Modifying Factor 2 52.667 105 0.99542727 3.35E-09 2.24E-06 
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    NFIX Nuclear Factor I/X (CCAAT-Binding Transcription 
Factor) 
152.667 293.333 0.942155925 2.36E-04 0.019048 
    NR2F2 Nuclear Receptor Subfamily 2, Group F, Member 2 64 122.333 0.934673752 3.48E-12 3.59E-09 
    UBE2O Ubiquitin-Conjugating Enzyme E2O 70.333 134.333 0.93353684 0.001155 0.057098 
21d Down IGF2 Insulin-Like Growth Factor 2 693 272.167 -1.348364967 4.75E-06 0.00556 
    COL19A1 Collagen, Type XIX, Alpha 1 111 56.5 -0.974236904 9.25E-05 0.030999 
    KV1.5 Potassium Channel, Voltage Gated Shaker Related 
Subfamily A, Member 5 
103.167 56.667 -0.864404663 3.33E-04 0.067915 
    SPON1 Spondin 1, Extracellular Matrix Protein 354.333 197.5 -0.843254538 5.83E-04 0.097901 
    KCNE3 Potassium Channel, Voltage Gated Subfamily E 
Regulatory Beta Subunit 3 
76 45.667 -0.734857931 9.98E-06 0.007333 
    AK4 Adenylate Kinase 4 122.667 74.333 -0.722662056 0.0001 0.031792 
    STK26 Serine/Threonine Protein Kinase 26 112 68.167 -0.71636039 6.63E-14 8E-10 
    STAC SH3 And Cysteine Rich Domain 182.667 123.833 -0.560813682 1.61E-04 0.038847 
    FRMD8 FERM Domain Containing 8 154 105.167 -0.550252846 1.95E-10 9.88E-07 
    GAB2 GRB2-Associated Binding Protein 2 108.667 75 -0.534946963 4.82E-06 0.00472 
21d Up MYH7 Myosin, Heavy Chain 7 3823.833 7102.833 0.89337499 0.000152 0.042455 
    ASB11 Ankyrin Repeat And SOCS Box Containing 11, E3 
Ubiquitin Protein Ligase 
211 325.5 0.625414544 2.52E-09 7.4E-06 
    FBXO40 F-Box Protein 40 2327.333 3514.833 0.594778425 4.44E-05 0.022724 
    PDGFC Platelet Derived Growth Factor C 303.667 446 0.554555157 0.000271 0.04963 
    CENPI Centromere Protein I 92.833 135.667 0.547351467 6.70E-05 0.024889 
    TP53INP2 Tumor Protein P53 Inducible Nuclear Protein 2 198.833 285.833 0.523614533 5.08E-08 0.000108 
    FAM214A Family With Sequence Similarity 214, Member A 487 693.667 0.510320787 5.76E-05 0.024889 
    AGO4 Argonaute RISC Catalytic Component 4 481.333 685.333 0.509769522 1.5E-08 0.000035 
    RP11-421N8.1 Known Processed Pseudogene 78.333 111.167 0.505026005 0.000192 0.082078 
    TRIM63 Tripartite Motif Containing 63, E3 Ubiquitin 
Protein Ligase 
1289.167 1781.167 0.466383727 0.00012 0.036078 
176d Down IGF2 Insulin-like Growth Factor 2 106 33.5 -1.661831264 3.71E-05 0.007756 
    GM5908 Predicted Gene, 5908 188.167 109 -0.787682945 4.73E-04 0.067648 
    IGFBP6 Insulin-like Growth Factor Binding Protein 6 212.167 127.167 -0.738477457 1.53E-03 0.079723 
    S100A10 S100 Calcium Binding Protein A10 162.333 98.5 -0.720763642 0.000928 0.060651 
    RP11-475C16.1  Known Processed Pseudogene 177 110.5 -0.679702991 4.65E-06 0.002168 
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    PGRMC1 Progesterone Receptor Membrane Component 1 144.667 93.5 -0.629694272 0.002257 0.098037 
    MYH11 Myosin, Heavy Chain 11 153.667 101.667 -0.595957508 4.01E-04 0.049115 
    PLN Phospholamban 1399.5 935.5 -0.581101928 4.28E-05 0.008203 
    PBX3 Pre-B-Cell Leukemia Homeobox 3 181 123.333 -0.553426927 0.000117 0.016085 
    LSM5 LSM5 Homolog, U6 Small Nuclear RNA Associated 165.667 114.333 -0.535037275 0.000215 0.024995 
176d Up SLC26A7 Solute Carrier Family 26 (Anion Exchanger), 
Member 7 
16.167 122.333 2.919723411 3.45E-07 0.00019 
    MYBPH Myosin Binding Protein H 6199.833 11363.5 0.874105921 0.001997 0.090982 
    SCMH1 Sex Comb On Midleg Homolog 1 91.333 140 0.616213435 1.49E-04 0.019792 
    CD83 CD83 Molecule 72.333 109.333 0.596000772 2.08E-03 0.092849 
    ASCC3 Activating Signal Cointegrator 1 Complex Subunit 3 72 106.333 0.562525112 1.94E-07 0.000141 
    STARD10 StAR-Related Lipid Transfer (START) Domain 
Containing 10 
152 220.333 0.535616447 1.36E-07 0.000088 
    SQSTM1 Sequestosome 1 7935 11454.5 0.529612357 0.001283 0.072929 
    MRPS9 Mitochondrial Ribosomal Protein S9 484.167 694.5 0.520470936 0.001655 0.082404 
    FN3K Fructosamine 3 Kinase 257.333 366.667 0.510830771 2.08E-03 0.092849 
    RP11-54I5.1  Known Processed Pseudogene 95.5 133.167 0.479660364 0.000221 0.039873 
 
 
Table 7. Differential expression of IGF2 at each time point resulting from alignment to Btau4.0, NCBIM37, and GRCh37 
Time point Genome Used Log2 Fold Change FDR 
d90 Btau 4.0 -0.153322372 0.940031 
  NCBIM37 -0.132757556 0.968236 
  GRCh37 -0.048943934 0.982465 
0d All  Btau 4.0 0.189293988 0.999377 
  NCBIM37 0.026875706 1 
  GRCh37 0.209468674 1 
0d RNAlater  Btau 4.0 0.626550539 1 
  NCBIM37 0.658531719 0.995091 
  GRCh37 0.44735522 1 
21d Btau 4.0 -1.348364967 0.00556 
  NCBIM37 -1.398066304 0.001778 
  GRCh37 -1.454378391 0.004247 
176d Btau 4.0 -1.661831264 0.007756 
  NCBIM37 -1.467358534 0.030943 
  GRCh37 -0.797811149 0.311453 
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Table 8. Enriched canonical pathways yielded by IPA analysis 
 
Time Point FDR Ingenuity Canonical Pathways Molecules z-score  -log(p-value) Adjusted p-value 
d90 0.05 EIF2 Signaling 7 2 6.7 2.00E-07 
    Estrogen Receptor Signaling 3 -- 2.51 0.00309 
    Aryl Hydrocarbon Receptor Signaling 3 -- 2.39 0.00407 
    Regulation of eIF4 and p70S6K Signaling 3 -- 2.34 0.00457 
    mTOR Signaling 3 -- 2.04 0.00912 
    Glycogen Degradation II 1 -- 1.64 0.02291 
    Glucocorticoid Receptor Signaling 3 -- 1.6 0.02512 
    Glycogen Degradation III 1 -- 1.57 0.02692 
    Assembly of RNA Polymerase III Complex 1 -- 1.53 0.02951 
    Hereditary Breast Cancer Signaling 2 -- 1.45 0.03548 
    Granzyme A Signaling 1 -- 1.35 0.04467 
d90 0.1 EIF2 Signaling 12 2.646 9.82 1.51E-10 
    mTOR Signaling 6 -- 3.43 0.00037 
    Aryl Hydrocarbon Receptor Signaling 5 -- 3.15 0.00071 
    Regulation of eIF4 and p70S6K Signaling 5 -- 3.07 0.00085 
    Estrogen Receptor Signaling 4 -- 2.41 0.00389 
    Glutamine Biosynthesis I 1 -- 2.3 0.00501 
    Cell Cycle Control of Chromosomal Replication 2 -- 2.09 0.00813 
    Formaldehyde Oxidation II (Glutathione-dependent) 1 -- 2 0.01000 
    Glucocorticoid Receptor Signaling 5 -- 1.9 0.01259 
    IGF-1 Signaling 3 -- 1.89 0.01288 
    Nucleotide Excision Repair Pathway 2 -- 1.87 0.01349 
    tRNA Charging 2 -- 1.79 0.01622 
    Role of Oct4 in Mammalian Embryonic Stem Cell Pluripotency 2 -- 1.65 0.02239 
    Hereditary Breast Cancer Signaling 3 -- 1.56 0.02754 
    Regulation of Cellular Mechanics by Calpain Protease 2 -- 1.48 0.03311 
    Glioblastoma Multiforme Signaling 3 -- 1.43 0.03715 
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Table 8 (cont.) 
    Remodeling of Epithelial Adherens Junctions 2 -- 1.34 0.04571 
    Glycogen Degradation II 1 -- 1.31 0.04898 
0dAll 0.05 Heme Biosynthesis from Uroporphyrinogen-III I 1 -- 1.7 0.01995 
    Biotin-carboxyl Carrier Protein Assembly 1 -- 1.7 0.01995 
    Glycine Cleavage Complex 1 -- 1.53 0.02951 
    Calcium-induced T Lymphocyte Apoptosis 2 -- 1.39 0.04074 
    Calcium Transport I 1 -- 1.36 0.04365 
    Heme Biosynthesis II 1 -- 1.36 0.04365 
0dAll 0.05 EIF2 Signaling 9 -1.633 3.55 0.00028 
    UVA-Induced MAPK Signaling 5 1.342 2.47 0.00339 
    Calcium Transport I 2 -- 2.35 0.00447 
    Calcium-induced T Lymphocyte Apoptosis 4 2 2.21 0.00617 
    Oxidative Phosphorylation 5 -- 2.08 0.00832 
    CDP-diacylglycerol Biosynthesis I 2 -- 1.85 0.01413 
    Estrogen Receptor Signaling 5 -- 1.82 0.01514 
    TR/RXR Activation 4 -- 1.79 0.01622 
    Phosphatidylglycerol Biosynthesis II (Non-plastidic) 2 -- 1.76 0.01738 
    CNTF Signaling 3 -- 1.67 0.02138 
    N-acetylglucosamine Degradation I 2 -- 1.47 0.03388 
    Retinoic acid Mediated Apoptosis Signaling 3 -- 1.44 0.03631 
    Actin Cytoskeleton Signaling 6 -- 1.41 0.03890 
    Heme Biosynthesis from Uroporphyrinogen-III I 1 -- 1.35 0.04467 
    Myo-inositol Biosynthesis 1 -- 1.35 0.04467 
    Biotin-carboxyl Carrier Protein Assembly 1 -- 1.35 0.04467 
    N-acetylglucosamine Degradation II 1 -- 1.35 0.04467 
    Mitochondrial Dysfunction 5 -- 1.33 0.04677 
0dRNAlater 0.05 Oxidative Phosphorylation 17 -- 10.9 1.26E-11 
    Mitochondrial Dysfunction 18 -- 8.62 2.40E-09 
    Actin Cytoskeleton Signaling 15 -- 4.96 0.00001 
    EIF2 Signaling 13 -2.714 4.45 0.00004 
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Table 8 (cont.) 
    Breast Cancer Regulation by Stathmin1 13 -- 4.3 0.00005 
    Phospholipase C Signaling 14 -0.577 3.88 0.00013 
    Regulation of Actin-based Motility by Rho 8 -1.414 3.6 0.00025 
    RhoGDI Signaling 11 -- 3.47 0.00034 
    Actin Nucleation by ARP-WASP Complex 6 -0.816 3.28 0.00052 
    Thrombin Signaling 11 -0.905 3.11 0.00078 
    Signaling by Rho Family GTPases 12 -0.577 2.9 0.00126 
    Gα12/13 Signaling 8 -2.121 2.87 0.00135 
    RhoA Signaling 8 -1.134 2.75 0.00178 
    Protein Kinase A Signaling 16 -- 2.7 0.00200 
    Estrogen Receptor Signaling 8 -- 2.64 0.00229 
    Cellular Effects of Sildenafil (Viagra) 8 -- 2.6 0.00251 
    Molecular Mechanisms of Cancer 15 -- 2.53 0.00295 
    Integrin Signaling 10 -1 2.41 0.00389 
    GM-CSF Signaling 5 1 2.27 0.00537 
    PAK Signaling 6 -0.816 2.24 0.00575 
    phagosome maturation 7 -- 2.19 0.00646 
    Polyamine Regulation in Colon Cancer 3 -- 2.15 0.00708 
    ILK Signaling 9 -1.414 2.15 0.00708 
    Gap Junction Signaling 8 -- 2.12 0.00759 
    Glioma Signaling 6 0.816 2.11 0.00776 
    Citrulline Biosynthesis 2 -- 2.07 0.00851 
    p53 Signaling 6 1.633 2.05 0.00891 
    Germ Cell-Sertoli Cell Junction Signaling 8 -- 2.04 0.00912 
    CDK5 Signaling 6 1.342 2.02 0.00955 
    UDP-N-acetyl-D-galactosamine Biosynthesis II 2 -- 1.96 0.01096 
    Tight Junction Signaling 8 -- 1.94 0.01148 
    HER-2 Signaling in Breast Cancer 5 -- 1.9 0.01259 
    Assembly of RNA Polymerase II Complex 4 -- 1.89 0.01288 
    Axonal Guidance Signaling 15 -- 1.87 0.01349 
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Table 8 (cont.) 
    Superpathway of Cholesterol Biosynthesis 3 -- 1.86 0.01380 
    Regulation of eIF4 and p70S6K Signaling 7 -1 1.76 0.01738 
    Glioblastoma Multiforme Signaling 7 -0.378 1.76 0.01738 
    Epithelial Adherens Junction Signaling 7 -- 1.76 0.01738 
    Cardiac Hypertrophy Signaling 9 -1 1.67 0.02138 
    CXCR4 Signaling 7 -1.89 1.67 0.02138 
    Synaptic Long Term Potentiation 6 -- 1.66 0.02188 
    Mevalonate Pathway I 2 -- 1.65 0.02239 
    Huntington's Disease Signaling 9 -- 1.61 0.02455 
    Superpathway of Citrulline Metabolism 2 -- 1.59 0.02570 
    Antiproliferative Role of Somatostatin Receptor 2 4 -- 1.56 0.02754 
    PCP pathway 4 -- 1.56 0.02754 
    Glucocorticoid Receptor Signaling 10 -- 1.53 0.02951 
    PI3K Signaling in B Lymphocytes 6 -- 1.53 0.02951 
    Granzyme B Signaling 2 -- 1.48 0.03311 
    Docosahexaenoic Acid (DHA) Signaling 3 -- 1.47 0.03388 
    Cardiac β-adrenergic Signaling 6 2.236 1.46 0.03467 
    Remodeling of Epithelial Adherens Junctions 4 -- 1.45 0.03548 
    Macropinocytosis Signaling 4 -- 1.45 0.03548 
    Glutamine Degradation I 1 -- 1.44 0.03631 
    Relaxin Signaling 6 1 1.43 0.03715 
    Superpathway of Geranylgeranyldiphosphate Biosynthesis I (via Mevalonate) 2 -- 1.43 0.03715 
    Renal Cell Carcinoma Signaling 4 -- 1.39 0.04074 
    Chemokine Signaling 4 1 1.39 0.04074 
    Melanoma Signaling 3 -- 1.39 0.04074 
    Rac Signaling 5 -0.447 1.38 0.04169 
    STAT3 Pathway  4 -- 1.36 0.04365 
    Sertoli Cell-Sertoli Cell Junction Signaling 7 -- 1.35 0.04467 
    Calcium Signaling 7 1 1.35 0.04467 
    Role of NFAT in Cardiac Hypertrophy 7 1.134 1.34 0.04571 
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Table 8 (cont.) 
    Role of Macrophages, Fibroblasts and Endothelial Cells in Rheumatoid Arthritis 10 -- 1.33 0.04677 
    cAMP-mediated signaling 8 1.633 1.32 0.04786 
0dRNAlater 0.1 Oxidative Phosphorylation 25 -- 14.3 5.01E-15 
    Mitochondrial Dysfunction 26 -- 10.4 3.98E-11 
    EIF2 Signaling 22 -2.5 6.93 1.17E-07 
    Actin Cytoskeleton Signaling 23 -- 6.3 5.01E-07 
    Signaling by Rho Family GTPases 22 0.218 5.19 6.46E-06 
    Thrombin Signaling 18 0 4.37 4.27E-05 
    Breast Cancer Regulation by Stathmin1 18 -- 4.37 4.27E-05 
    Integrin Signaling 18 0 4.08 8.32E-05 
    RhoA Signaling 13 -0.302 3.85 0.00014 
    Regulation of eIF4 and p70S6K Signaling 14 0.378 3.61 0.00025 
    Cellular Effects of Sildenafil (Viagra) 13 -- 3.61 0.00025 
    Axonal Guidance Signaling 28 -- 3.46 0.00035 
    Gα12/13 Signaling 12 -1.155 3.44 0.00036 
    Huntington's Disease Signaling 18 -- 3.38 0.00042 
    PAK Signaling 10 0 3.27 0.00054 
    Germ Cell-Sertoli Cell Junction Signaling 14 -- 3.21 0.00062 
    Estrogen Receptor Signaling 12 -- 3.12 0.00076 
    PI3K Signaling in B Lymphocytes 12 -- 3.09 0.00081 
    Assembly of RNA Polymerase II Complex 7 -- 3.01 0.00098 
    Gap Junction Signaling 13 -- 2.85 0.00141 
    Phospholipase C Signaling 17 -0.775 2.75 0.00178 
    Rac Signaling 10 0 2.75 0.00178 
    Chemokine Signaling 8 0.707 2.73 0.00186 
    Dopamine-DARPP32 Feedback in cAMP Signaling 13 1.508 2.7 0.00200 
    Cardiac Hypertrophy Signaling 16 -0.5 2.66 0.00219 
    UDP-N-acetyl-D-galactosamine Biosynthesis II 3 -- 2.63 0.00234 
    Regulation of Actin-based Motility by Rho 9 -1.667 2.61 0.00245 
    Sphingosine-1-phosphate Signaling 10 1.265 2.59 0.00257 
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Table 8 (cont.) 
    ILK Signaling 14 0.277 2.58 0.00263 
    Protein Kinase A Signaling 23 -- 2.49 0.00324 
    Glioma Signaling 9 1 2.48 0.00331 
    CXCR4 Signaling 12 -1.155 2.45 0.00355 
    RhoGDI Signaling 13 -- 2.43 0.00372 
    B Cell Receptor Signaling 13 -- 2.37 0.00427 
    p70S6K Signaling 10 0.632 2.32 0.00479 
    phagosome maturation 10 -- 2.29 0.00513 
    PI3K/AKT Signaling 10 -0.632 2.22 0.00603 
    FAK Signaling 8 -- 2.18 0.00661 
    Molecular Mechanisms of Cancer 21 -- 2.15 0.00708 
    RANK Signaling in Osteoclasts 8 -- 2.15 0.00708 
    Lymphotoxin β Receptor Signaling 6 2.236 2.14 0.00724 
    Tight Junction Signaling 12 -- 2.13 0.00741 
    Role of Macrophages, Fibroblasts and Endothelial Cells in Rheumatoid Arthritis 18 -- 2.13 0.00741 
    Docosahexaenoic Acid (DHA) Signaling 5 -- 2.12 0.00759 
    Actin Nucleation by ARP-WASP Complex 6 -0.816 2.06 0.00871 
    Relaxin Signaling 10 1.633 1.95 0.01122 
    Role of NFAT in Cardiac Hypertrophy 12 1.155 1.91 0.01230 
    p53 Signaling 8 1.414 1.88 0.01318 
    CD28 Signaling in T Helper Cells 9 1 1.88 0.01318 
    PTEN Signaling 9 -0.707 1.88 0.01318 
    CDK5 Signaling 8 1.134 1.86 0.01380 
    Ceramide Signaling 7 -0.816 1.86 0.01380 
    GM-CSF Signaling 6 1.342 1.86 0.01380 
    Aryl Hydrocarbon Receptor Signaling 10 -- 1.84 0.01445 
    Glucocorticoid Receptor Signaling 16 -- 1.81 0.01549 
    Prostate Cancer Signaling 7 -- 1.8 0.01585 
    mTOR Signaling 12 0.707 1.75 0.01778 
    Ephrin A Signaling 5 -- 1.75 0.01778 
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Table 8 (cont.) 
    Glioblastoma Multiforme Signaling 10 0.632 1.73 0.01862 
    NGF Signaling 8 1.89 1.67 0.02138 
    Remodeling of Epithelial Adherens Junctions 6 -- 1.67 0.02138 
    Macropinocytosis Signaling 6 -- 1.67 0.02138 
    CREB Signaling in Neurons 11 1 1.67 0.02138 
    fMLP Signaling in Neutrophils 8 0 1.65 0.02239 
    iCOS-iCOSL Signaling in T Helper Cells 8 2.121 1.65 0.02239 
    Interferon Signaling 4 -- 1.65 0.02239 
    Melatonin Signaling 6 -1.633 1.62 0.02399 
    CNTF Signaling 5 0.447 1.61 0.02455 
    Endometrial Cancer Signaling 5 -- 1.61 0.02455 
    Citrulline Biosynthesis 2 -- 1.6 0.02512 
    Renal Cell Carcinoma Signaling 6 -- 1.59 0.02570 
    Androgen Signaling 8 -- 1.59 0.02570 
    Cardiac β-adrenergic Signaling 9 2.121 1.57 0.02692 
    Production of Nitric Oxide and Reactive Oxygen Species in Macrophages 11 0.905 1.53 0.02951 
    Calcium Transport I 2 -- 1.5 0.03162 
    Polyamine Regulation in Colon Cancer 3 -- 1.5 0.03162 
    14-3-3-mediated Signaling 8 -- 1.47 0.03388 
    CCR3 Signaling in Eosinophils 8 -- 1.47 0.03388 
    IL-8 Signaling 11 -0.905 1.47 0.03388 
    HER-2 Signaling in Breast Cancer 6 -- 1.47 0.03388 
    Glioma Invasiveness Signaling 5 0.447 1.46 0.03467 
    PKCθ Signaling in T Lymphocytes 8 -- 1.45 0.03548 
    Clathrin-mediated Endocytosis Signaling 11 -- 1.45 0.03548 
    T Cell Receptor Signaling 7 -- 1.45 0.03548 
    Synaptic Long Term Potentiation 8 -- 1.43 0.03715 
    ERK/MAPK Signaling 11 0.905 1.42 0.03802 
    Telomerase Signaling 7 1.342 1.41 0.03890 
    Nitric Oxide Signaling in the Cardiovascular System 7 -0.378 1.39 0.04074 
 80 
 
Table 8 (cont.) 
    Induction of Apoptosis by HIV1 5 1.342 1.38 0.04169 
    ErbB4 Signaling 5 1 1.38 0.04169 
    Paxillin Signaling 7 1.342 1.37 0.04266 
    Melanoma Signaling 4 -- 1.36 0.04365 
    Epithelial Adherens Junction Signaling 9 -- 1.35 0.04467 
21d 0.05 Hepatic Fibrosis / Hepatic Stellate Cell Activation 4 -- 2.93 0.00117 
    Autophagy 2 -- 2.43 0.00372 
    eNOS Signaling 3 -- 2.25 0.00562 
    Regulation of eIF4 and p70S6K Signaling 3 -- 2.22 0.00603 
    AMPK Signaling 3 -- 1.98 0.01047 
    EIF2 Signaling 3 -- 1.94 0.01148 
    Serine Biosynthesis 1 -- 1.9 0.01259 
    Superpathway of Serine and Glycine Biosynthesis I 1 -- 1.75 0.01778 
    VEGF Signaling 2 -- 1.64 0.02291 
    Glioma Signaling 2 -- 1.62 0.02399 
    Amyotrophic Lateral Sclerosis Signaling 2 -- 1.59 0.02570 
    Sphingosine-1-phosphate Signaling 2 -- 1.51 0.03090 
    DNA Double-Strand Break Repair by Non-Homologous End Joining 1 -- 1.46 0.03467 
    Cellular Effects of Sildenafil (Viagra) 2 -- 1.37 0.04266 
    Cardiomyocyte Differentiation via BMP Receptors 1 -- 1.31 0.04898 
21d 0.1 Arginine Degradation I (Arginase Pathway) 2 -- 3.93 0.00012 
    Hepatic Fibrosis / Hepatic Stellate Cell Activation 5 -- 2.85 0.00141 
    Pyrimidine Ribonucleotides Interconversion 2 -- 2.13 0.00741 
    PAK Signaling 3 -- 2.12 0.00759 
    VEGF Signaling 3 -- 2.09 0.00813 
    Fcγ Receptor-mediated Phagocytosis in Macrophages and Monocytes 3 -- 2.07 0.00851 
    Salvage Pathways of Pyrimidine Ribonucleotides 3 -- 2.07 0.00851 
    Pyrimidine Ribonucleotides De Novo Biosynthesis 2 -- 2.07 0.00851 
    Proline Degradation 1 -- 2.05 0.00891 
    4-hydroxyproline Degradation I 1 -- 2.05 0.00891 
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Table 8 (cont.) 
    Autophagy 2 -- 1.94 0.01148 
    Sphingosine-1-phosphate Signaling 3 -- 1.89 0.01288 
    Fatty Acid β-oxidation III (Unsaturated, Odd Number) 1 -- 1.87 0.01349 
    Serine Biosynthesis 1 -- 1.65 0.02239 
    Insulin Receptor Signaling 3 -- 1.65 0.02239 
    eNOS Signaling 3 -- 1.58 0.02630 
    Urea Cycle 1 -- 1.57 0.02692 
    Arginine Degradation VI (Arginase 2 Pathway) 1 -- 1.57 0.02692 
    Regulation of eIF4 and p70S6K Signaling 3 -- 1.55 0.02818 
    Protein Kinase A Signaling 5 -- 1.52 0.03020 
    Superpathway of Serine and Glycine Biosynthesis I 1 -- 1.51 0.03090 
    Pyridoxal 5'-phosphate Salvage Pathway 2 -- 1.47 0.03388 
    Hypoxia Signaling in the Cardiovascular System 2 -- 1.46 0.03467 
    Citrulline Biosynthesis 1 -- 1.45 0.03548 
    GABA Receptor Signaling 2 -- 1.44 0.03631 
    Growth Hormone Signaling 2 -- 1.42 0.03802 
    Chemokine Signaling 2 -- 1.39 0.04074 
    RhoGDI Signaling 3 -- 1.37 0.04266 
    B Cell Receptor Signaling 3 -- 1.35 0.04467 
    AMPK Signaling 3 -- 1.33 0.04677 
    IL-8 Signaling 3 -- 1.3 0.05012 
176d 0.05 Amyloid Processing 6 -- 4.99 1.02E-05 
    ILK Signaling 10 0.333 4.81 1.55E-05 
    Integrin Signaling 10 1 4.52 0.00003 
    PTEN Signaling 7 -1.89 3.78 0.00017 
    Regulation of Cellular Mechanics by Calpain Protease 5 2 3.62 0.00024 
    Mouse Embryonic Stem Cell Pluripotency 6 0.816 3.46 0.00035 
    IGF-1 Signaling 6 2.236 3.41 0.00039 
    IL-17 Signaling 5 -- 3.15 0.00071 
    Role of --OG in Mammalian Embryonic Stem Cell Pluripotency 6 1.342 3.1 0.00079 
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Table 8 (cont.) 
    Actin Cytoskeleton Signaling 8 -- 2.86 0.00138 
    IL-22 Signaling 3 -- 2.79 0.00162 
    FAK Signaling 5 -- 2.78 0.00166 
    CNTF Signaling 4 2 2.78 0.00166 
    Endometrial Cancer Signaling 4 -- 2.78 0.00166 
    IL-2 Signaling 4 -- 2.74 0.00182 
    Role of JAK family kinases in IL-6-type Cytokine Signaling 3 -- 2.74 0.00182 
    EGF Signaling 4 2 2.66 0.00219 
    IL-17A Signaling in Airway Cells 4 -- 2.44 0.00363 
    IL-15 Signaling 4 -- 2.4 0.00398 
    Oncostatin M Signaling 3 -- 2.35 0.00447 
    IL-6 Signaling 5 1.342 2.24 0.00575 
    Type II Diabetes Mellitus Signaling 5 -- 2.23 0.00589 
    PDGF Signaling 4 2 2.16 0.00692 
    PI3K/AKT Signaling 5 1.342 2.14 0.00724 
    Melanoma Signaling 3 -- 2.1 0.00794 
    Regulation of the Epithelial-Mesenchymal Transition Pathway 6 -- 2.01 0.00977 
    FGF Signaling 4 2 2.01 0.00977 
    G Beta Gamma Signaling 4 -- 1.96 0.01096 
    RAR Activation 6 -- 1.95 0.01122 
    VEGF Signaling 4 1 1.89 0.01288 
    Epithelial Adherens Junction Signaling 5 -- 1.84 0.01445 
    UVB-Induced MAPK Signaling 3 -- 1.82 0.01514 
    Nitric Oxide Signaling in the Cardiovascular System 4 1 1.77 0.01698 
    ErbB2-ErbB3 Signaling 3 -- 1.73 0.01862 
    Germ Cell-Sertoli Cell Junction Signaling 5 -- 1.68 0.02089 
    Tight Junction Signaling 5 -- 1.61 0.02455 
    Pyridoxal 5'-phosphate Salvage Pathway 3 -- 1.6 0.02512 
    Wnt/β-catenin Signaling 5 0 1.59 0.02570 
    Role of PI3K/AKT Signaling in the Pathogenesis of Influenza 3 -- 1.57 0.02692 
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Table 8 (cont.) 
    IL-15 Production 2 -- 1.54 0.02884 
    Diphthamide Biosynthesis 1 -- 1.54 0.02884 
    Coenzyme A Biosynthesis 1 -- 1.54 0.02884 
    p70S6K Signaling 4 2 1.53 0.02951 
    Agrin Interactions at Neuromuscular Junction 3 -- 1.52 0.03020 
    Sertoli Cell-Sertoli Cell Junction Signaling 5 -- 1.51 0.03090 
    AMPK Signaling 5 0 1.5 0.03162 
    Caveolar-mediated Endocytosis Signaling 3 -- 1.49 0.03236 
    IL-3 Signaling 3 -- 1.49 0.03236 
    JAK/Stat Signaling 3 -- 1.47 0.03388 
    EIF2 Signaling 5 0 1.45 0.03548 
    Estrogen Receptor Signaling 4 -- 1.44 0.03631 
    Role of BRCA1 in DNA Damage Response 3 -- 1.38 0.04169 
    MIF-mediated Glucocorticoid Regulation 2 -- 1.38 0.04169 
    Acute Myeloid Leukemia Signaling 3 -- 1.37 0.04266 
    Insulin Receptor Signaling 4 -- 1.37 0.04266 
    Inhibition of Angiogenesis by TSP1 2 -- 1.36 0.04365 
    IL-17A Signaling in Fibroblasts 2 -- 1.34 0.04571 
    Prostate Cancer Signaling 3 -- 1.33 0.04677 
    Eumelanin Biosynthesis 1 -- 1.32 0.04786 
    Lysine Degradation II 1 -- 1.32 0.04786 
    Lysine Degradation V 1 -- 1.32 0.04786 
    Autophagy 2 -- 1.32 0.04786 
    Melanocyte Development and Pigmentation Signaling 3 -- 1.3 0.05012 
176d 0.1 Integrin Signaling 15 0.832 4.76 1.74E-05 
    Amyloid Processing 7 -- 4.12 7.59E-05 
    ILK Signaling 13 1.155 3.91 0.00012 
    EGF Signaling 7 1.134 3.86 0.00014 
    Regulation of Cellular Mechanics by Calpain Protease 7 1.342 3.81 0.00015 
    FAK Signaling 8 -- 3.39 0.00041 
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Table 8 (cont.) 
    Role of --OG in Mammalian Embryonic Stem Cell Pluripotency 9 1.633 3.34 0.00046 
    Actin Cytoskeleton Signaling 13 -- 3.26 0.00055 
    IL-6 Signaling 9 1.667 3.2 0.00063 
    CNTF Signaling 6 2.449 3.19 0.00065 
    IL-17 Signaling 7 -- 3.18 0.00066 
    PTEN Signaling 9 -2.333 3.15 0.00071 
    Mouse Embryonic Stem Cell Pluripotency 8 0.707 3.14 0.00072 
    Autophagy 5 -- 3.11 0.00078 
    IGF-1 Signaling 8 2.449 3.08 0.00083 
    PDGF Signaling 7 1.134 3 0.00100 
    NRF2-mediated Oxidative Stress Response 11 0.447 2.91 0.00123 
    Role of JAK family kinases in IL-6-type Cytokine Signaling 4 -- 2.81 0.00155 
    Melanocyte Development and Pigmentation Signaling 7 1.134 2.78 0.00166 
    G Beta Gamma Signaling 7 -- 2.66 0.00219 
    Glioblastoma Multiforme Signaling 9 -0.333 2.5 0.00316 
    Caveolar-mediated Endocytosis Signaling 6 -- 2.48 0.00331 
    Colorectal Cancer Metastasis Signaling 12 1.508 2.46 0.00347 
    Endometrial Cancer Signaling 5 -- 2.39 0.00407 
    Nitric Oxide Signaling in the Cardiovascular System 7 0.378 2.35 0.00447 
    IL-2 Signaling 5 2 2.35 0.00447 
    Estrogen Receptor Signaling 8 -- 2.34 0.00457 
    Gap Junction Signaling 9 -- 2.33 0.00468 
    Regulation of the Epithelial-Mesenchymal Transition Pathway 10 -- 2.33 0.00468 
    Paxillin Signaling 7 0.816 2.33 0.00468 
    Cellular Effects of Sildenafil (Viagra) 8 -- 2.3 0.00501 
    Reelin Signaling in Neurons 6 -- 2.26 0.00550 
    Germ Cell-Sertoli Cell Junction Signaling 9 -- 2.24 0.00575 
    RAR Activation 10 -- 2.23 0.00589 
    TR/RXR Activation 6 -- 2.1 0.00794 
    FGF Signaling 6 1.633 2.1 0.00794 
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Table 8 (cont.) 
    Role of Macrophages, Fibroblasts and Endothelial Cells in Rheumatoid Arthritis 13 -- 2.06 0.00871 
    Antiproliferative Role of Somatostatin Receptor 2 5 0 2.03 0.00933 
    RANK Signaling in Osteoclasts 6 -- 2.03 0.00933 
    IL-17A Signaling in Airway Cells 5 -- 2.01 0.00977 
    Type II Diabetes Mellitus Signaling 7 -- 1.99 0.01023 
    Epithelial Adherens Junction Signaling 8 -- 1.98 0.01047 
    Melanoma Signaling 4 -- 1.98 0.01047 
    Hypoxia Signaling in the Cardiovascular System 5 -- 1.98 0.01047 
    p70S6K Signaling 6 1.134 1.95 0.01122 
    IL-15 Signaling 5 -- 1.95 0.01122 
    VEGF Signaling 6 0.816 1.94 0.01148 
    AMPK Signaling 9 0.378 1.94 0.01148 
    Role of NFAT in Cardiac Hypertrophy 9 0.333 1.94 0.01148 
    IL-22 Signaling 3 -- 1.9 0.01259 
    CXCR4 Signaling 8 0 1.89 0.01288 
    UDP-N-acetyl-D-galactosamine Biosynthesis II 2 -- 1.87 0.01349 
    Clathrin-mediated Endocytosis Signaling 9 -- 1.85 0.01413 
    Role of Osteoblasts, Osteoclasts and Chondrocytes in Rheumatoid Arthritis 10 -- 1.83 0.01479 
    Antiproliferative Role of TOB in T Cell Signaling 3 -- 1.81 0.01549 
    JAK/Stat Signaling 5 1.342 1.8 0.01585 
    Cardiac Hypertrophy Signaling 10 1.897 1.78 0.01660 
    STAT3 Pathway 5 -- 1.78 0.01660 
    GNRH Signaling 7 1.134 1.77 0.01698 
    Thrombin Signaling 9 0 1.77 0.01698 
    Human Embryonic Stem Cell Pluripotency 7 -- 1.69 0.02042 
    UVB-Induced MAPK Signaling 4 -- 1.64 0.02291 
    Acute Phase Response Signaling 8 2.828 1.64 0.02291 
    Wnt/β-catenin Signaling 8 1.134 1.64 0.02291 
    Cleavage and Polyadenylation of Pre-mRNA 2 -- 1.62 0.02399 
    Lymphotoxin β Receptor Signaling 4 2 1.61 0.02455 
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Table 8 (cont.) 
    Sphingosine-1-phosphate Signaling 6 0.816 1.61 0.02455 
    Prostate Cancer Signaling 5 -- 1.58 0.02630 
    eNOS Signaling 7 1.633 1.57 0.02692 
    ErbB2-ErbB3 Signaling 4 -- 1.54 0.02884 
    Sertoli Cell-Sertoli Cell Junction Signaling 8 -- 1.52 0.03020 
    PPARα/RXRα Activation 8 -1.134 1.51 0.03090 
    Gαq Signaling 7 0.378 1.5 0.03162 
    Oncostatin M Signaling 3 -- 1.5 0.03162 
    Inhibition of Angiogenesis by TSP1 3 -- 1.5 0.03162 
    p38 MAPK Signaling 6 0 1.48 0.03311 
    P2Y Purigenic Receptor Signaling Pathway 6 1.633 1.45 0.03548 
    Apoptosis Signaling 5 0 1.45 0.03548 
    Protein Ubiquitination Pathway 10 -- 1.43 0.03715 
    IL-1 Signaling 5 2 1.41 0.03890 
    mTOR Signaling 8 2.646 1.4 0.03981 
    ERK5 Signaling 3 1 1.4 0.03981 
    Estrogen-Dependent Breast Cancer Signaling 4 1 1.4 0.03981 
    PI3K/AKT Signaling 6 1.633 1.39 0.04074 
    Notch Signaling 3 -- 1.38 0.04169 
    PPAR Signaling 5 0.447 1.36 0.04365 
    CD40 Signaling 4 2 1.36 0.04365 
    Non-Small Cell Lung Cancer Signaling 4 1 1.36 0.04365 
    Docosahexaenoic Acid (DHA) Signaling 3 -- 1.35 0.04467 
    Glioma Signaling 5 0.447 1.34 0.04571 
    Angiopoietin Signaling 4 -- 1.34 0.04571 
    Role of PI3K/AKT Signaling in the Pathogenesis of Influenza 4 -- 1.34 0.04571 
    Adipogenesis pathway 6 -- 1.33 0.04677 
    Erythropoietin Signaling 4 -- 1.32 0.04786 
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Figure 2. Overlap of DEGs with FDR ≤ 0.10 for each time point 
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Figure 3. Boxplot of IGF2 expression at each time point for yielded from Btau4.0, NCBIM37, and GRCh37 alignments 
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